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Beta3-adrenergic receptorAdipose tissue plays an essential role in regulating energy balance through its metabolic, cellular and endocrine
functions. Adipose tissue has been historically classiﬁed into anabolic white adipose tissue and catabolic brown
adipose tissue. An explosion of new data, however, points to the remarkable heterogeneity among the cells
types that can become adipocytes, as well as the inherentmetabolic plasticity of mature cells. These data indicate
that targeting cellular and metabolic plasticity of adipose tissue might provide new avenues for treatment of
obesity-related diseases. This review will discuss the developmental origins of adipose tissue, the cellular com-
plexity of adipose tissues, and the identiﬁcation of progenitors that contribute to adipogenesis throughout devel-
opment.Wewill touch upon the pathological remodeling of adipose tissue and discuss how our understanding of
adipose tissue remodeling can uncover new therapeutic targets. This article is part of a Special Issue entitled:
Modulation of Adipose Tissue in Health and Disease.
© 2013 Published by Elsevier B.V.1. Introduction
Adipose tissue (AT) is an organ that typically functions as the body's
energy reservoir by storing energy in the form of triglyceride (TG) in
times of surfeit, and mobilizing energy in the form of fatty acids in
times of need. Because fatty acids and their metabolic products can be
toxic, homeostatic mechanisms exist to ﬁnely balance lipid storage and
mobilization to prevent accumulation of potentially toxic lipids in pe-
ripheral organs [1]. The ability of the adipose organ to buffer variations
in energy supply and demand is achieved by integrated endocrine and
metabolic responses, as well as through dynamic changes in cellular
composition [2]. The buffering capacity of adipose tissue can be exceeded
during chronic overnutrition, resulting in the spillover of lipids from fat
tissue and their pathological accumulationwithin othermajormetabolic
organs. Metabolites derived from this ectopic lipid accumulation impair
insulin action in peripheral tissues and insulin production by the pancre-
as [1,3] in a process termed lipotoxicity [1]. Thus, one might anticipate
that promoting the ability of AT to store or oxidize excess lipid energy
would have beneﬁcial effects on whole body metabolism.
White adipose tissue (WAT) can expand its energy-buffering capacity
by fat cell hypertrophy and/or by hyperplasia from committed progeni-
tors. Although AT mass is a rough predictor of diabetes risk, the amount
of fat tissue matters less than the ability of the tissue to act as an energy
buffer [3]. For example, patients with mutation of phosphatase andion of Adipose Tissue in Health
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eman).
sevier B.V.tensin homolog [4] are obese yet insulin sensitive, whereas patients
with familial partial lipodystrophy exhibit ectopic lipid accumulation
and are severely insulin resistant and diabetic [5]. Similarly, limiting AT
expansion during overnutrition in rodents promotes ectopic lipid accu-
mulation and accelerates diabetes [6], whereas expanding storage capa-
bility reduces ectopic triglyceride accumulation and improves insulin
sensitivity [7].
In contrast toWAT, brown adipose tissue (BAT) is a highly oxidative
tissue containingmultilocular fat cellswith abundantmitochondria that
oxidize fatty acids and generate heat via uncoupling protein 1 (UCP1).
Classic BAT is clearly the dominant site of nonshivering thermogenesis
in rodents [8], and there is little doubt that variations in thermoregula-
tory thermogenesis can contribute greatly to disturbances in energy
balance [9].Whether classic BAT is important for energy balance during
nutritional challenges continues to be amatter of debate [10–12]. How-
ever, the recent identiﬁcation of BAT in humans [13] raises the possibil-
ity that pharmacological activation of BAT might combat obesity and
improve insulin action [14], as it clearly does in rodents [15].
WAT has been historically deﬁned by anatomical location and the
presence of parenchymal cells containing a single large lipid droplet
and sparsemitochondria lacking UCP1. However,WAT can be remodeled
under various physiological and pharmacological conditions to a more
oxidative phenotype resembling that of BAT, including the presence of
multilocular cells that are rich inmitochondria containing UCP1. This cat-
abolic remodeling is prominent in rodents and can be brought about by
activating adipocyte receptors such as β3-adrenergic receptors (β3-AR)
and peroxisome proliferator-activated receptor γ (PPARγ). Importantly,
activation of BAT, and possibly brown adipocytes (BA) in WAT [16], can
have anti-obesity effects and improve glucose homeostasis in rodent
models of type 2 diabetes [15]. Recent observations indicating that BA
in human supraclavicular BAT resemble those that can be recruited in
Table 1
Genetic tracing of adipocyte progenitors during development and in adult adipose tissue.
Lineage
markers
Developmental origin Lineage-derived
adipose depots
Reference
Myf5 Paraxial mesoderm
Myogenic
BAT (interscapular, perirenal)
WAT
[39]
[41]
Pax7 Somite
(dermomyotome)
Myogenic
BAT (interscapular) [43]
PDGFRβ Mesenchyme
MSC
WAT (retroperitoneal,
inguinal)
[52]
PPARγ Adipogenic WAT (retroperitoneal,
inguinal)
[52]
SM22 Vascular smooth muscle
cells (VSMC)
Perivascular adipose tissue [36]
[37]
Sox10 Neural crest Facial WAT (salivary gland
and ear)
[34]
VE-cadherin Endothelial cells WAT and BAT [61]
[65]
LysM Myeloid cells BM-derived adipocytes [69]
PDGFRα Paraxial mesoderm
MSC
WA/inducible BA [56]
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beneﬁt in man [17,18].
Work in experimental models has demonstrated the remarkable
plasticity of the adipose organ [19], and it is clear that beneﬁcial effects
can be achieved by promoting either anabolic or catabolic phenotypes.
If modulation of adipocyte phenotypes is to be realized as a therapeutic
approach, then it becomes essential to develop a better understanding
of the cell types and extrinsic signals that contribute to AT development
and plasticity. In this review, we discuss the origin of AT, including a
historic description of AT ontogeny and the current understanding of
adipocyte progenitors. We examine depot-speciﬁc heterogeneity in
the origin and transcriptional requirements of adipogenesis, and intro-
duce the concept of an adipogenic tissue niche that involves cellular and
matrix components. Finally, we discuss AT plasticity and how targeting
adipocyte receptors can be used to improve AT function.
2. Development of adipose tissue
Adipogenesis is a highly ordered process that is initiated during
development and continues throughout life [20]. Seminal histological
experiments conducted in the 1960s deﬁned the ontogeny of AT and
provided a foundation for delineating adipocyte progenitors usingmod-
ern genetic tracing techniques [21,22]. In brief, AT organogenesis can be
divided into distinct stages, which are characterized by cellular compo-
sition and differentiation status. Presumptive AT ﬁrst appears as loose
connective tissues which contain extracellular matrix with sparse,
mostly mesenchymal, cells [21]. These unvascularized “prestructural
territories” appear to provide a framework for further recruitment of
progenitors and subsequent adipogenesis [22]. Over time, mesenchy-
mal cells aggregate to form “mesenchymal lobules,”which have a retic-
ular structure [21]. Major events of this stage include vascularization
and expansion of mesenchymal cells [23–25]. Proliferation kinetic stud-
ies in rodents have shown that mitoses are mostly found in poorly dif-
ferentiated mesenchymal cells that subsequently differentiate into
adipocytes [26,27]. Differentiating progenitors accumulate micro-lipid
droplets to form “primitive fat lobules” [22,28]. Adipogenesis appears
to be guided in a central to peripheral gradient by the developing capil-
lary networks that bud from the central vasculature [22]. Eventually,
the primitive AT matures to form “deﬁnitive fat lobules” that are
enclosed by connective tissue septae [23,29]. Finally, terminal differen-
tiation and enlargement of individual adipocytes occur, which are the
major modes of postnatal AT growth [30].
The developmental timing of adipogenesis differs among species, and
varies by anatomical location. AT development is initiated during the
second trimester in humans [23,24,29], and during the perinatal period
in rodents [27,31]. Subcutaneous AT generally develops before abdomi-
nal adipose tissue in rodents [26,27] and humans [32]. Overall, differen-
tiation progresses in an anterior to posterior, rostral to caudal, and dorsal
to ventral direction in various species, including man [25,28]. BAT de-
velops before WAT, and can easily be identiﬁed at birth in most mam-
mals [33]. BAT histogenesis resembles that of WAT, but has slightly
denser andmore compact reticular structures during primitive fat lobule
formation [22].
3. Adipocyte progenitors
Application of the stem cell concept to AT biology launched an explo-
sion of research into the molecular characteristics and differentiation
potential of progenitor cells that reside in AT. Although the precise iden-
tity of adipocyte progenitors in humans remains unknown, modern ap-
proaches, including in vivo lineage tracing and FACS-based prospective
analyses, have enabled extensive characterization of adipocyte progeni-
tors in mouse models. As discussed below, growing evidence suggests
that several cell types can give rise to adipocytes in vivo, depending on
developmental stage, anatomic location, and physiological conditions.3.1. Adipocyte progenitors during development
Based on earlier histogenetic studies, a mesodermal origin of AT has
beenwidely accepted. However, the fact that AT depots appear at differ-
ent times and possess distinct molecular characteristics suggests that
there may be regional heterogeneity among AT depots. In addition,
genetic lineage tracing using Cre-LoxP recombination has shown di-
verse developmental origins of AT (Table 1). For example, lineage trac-
ingwith amarker of neural crest (Sox10) demonstrated that adipocytes
in the head and neck are generated from the neuroectoderm, rather
than the mesoderm [34]. Interestingly, the bones and muscles of the
skull and face also appear to be of neural crest origin [35], suggesting
that local mesenchymal lineages have a common origin in a given ana-
tomic location. Similarly, lineage tracing showed that SM22-Cre, which
is active in vascular smoothmuscle cells (VSMC) and surroundingmes-
enchyme, marks perivascular adipose tissue (PVAT), indicating a close
lineage relationship between PVAT and VSMC [36,37].
Notably, in vivo fate-mapping and lineage-tracing studies have
established that cells expressing the early myogenic factor Myf5 can
give rise to both skeletal myocytes and BA in the interscapular and
perirenal BAT depots [38,39]. Moreover, the BA that emerge in WAT in
response to β3-AR stimulation or cold stress are not tagged by Myf5-
Cre, indicating that the origins of classic BA (which reside in BAT) and
inducible BA in WAT are distinct [39]. Because the Myf5 promoter is
transiently activated in undifferentiated paraxial mesoderm, cells with
a history of Myf5 expression give rise to multiple types of cells, includ-
ing cartilage and bone [40]. In this regard, recent ﬁndings demonstrate
that adipocytes derived from Myf5-expressing progenitors are hetero-
geneously expressedwithin a givenWAT depot [41]. Asmentioned ear-
lier, AT depots develop over time in a rostral to caudal direction [20,42].
Conditional deletion of PTEN in Myf5+ expressing cells speciﬁcally in-
creases adiposity in the upper body [41], implying earlier developmen-
tal timing of Myf5+ cell-derived adipocytes. It is not clear, however,
whether Myf5 is an important determinant of adipogenesis or whether
tagging by Myf5-Cre reﬂects transient expression within undifferentiat-
ed paraxial mesoderm. Although constitutive Cre-LoxP systems have
provided deﬁnitive evidence of the contribution of speciﬁc lineages to
AT, use of inducible reporter systems is required to deﬁne the timing of
lineage speciﬁcation. In this regard, lineage tracing with an inducible
Pax7reporter demonstrated that the developmental divergence be-
tween BAT and muscle occurs around E10.5 to E12.5 [43].
Gene knockout studies in mice indicate that the transcriptional pro-
gram controlling adipogenesis varies among fat depots. For example,
genetic ablation of CEBPα impairs development of subcutaneous and
gonadal WAT, whereas mammary WAT and interscapular BAT are
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in interscapular BAT formation, whereas WAT is relatively unaffected
[45]. Conversely, fat-speciﬁc inactivation of canonical hedgehog signal-
ing causes loss of WAT, but not BAT [46]. In humans, inherited partial
lipodystrophies often do not appear until adolescence, and then affect
certain fat depots (e.g., subcutaneous WAT) and not others [47–49].
Together, these observations support a theory of inter-depot heterogene-
ity in developmental origin and transcriptional control of adipogenesis.
Despite variations in molecular signatures of adipocyte progenitors
among individual depots [50,51], it is widely agreed that PPARγ is the
requisite master regulator for differentiation of committed progenitors
into adipocytes in all AT depots. Utilizing inducible PPARγ reporter
strains, Tang et al. identiﬁed a population of committed progenitors
that give rise to adipocytes during perinatal expansion of inguinal and
retroperitoneal WAT [52]. Commitment, as deduced from reporter
gene expression, occurs prenatally and the progenitors undergo dra-
matic postnatal expansion. Surprisingly, the PPARγ gene was active,
as indicated by reporter gene expression, yet known PPARγ targets
(e.g., CEBPα, fatty acid binding protein 4, leptin) were not expressed.
This may reﬂect the sensitivity of the reporter system to very low levels
of PPARγ that are found in pre-adipocytes, or the absence of mediators
that initiate PPARγ activity of quiescent preadipocytes. Interestingly,
many of these committed preadipocytes in this study had a perivascular
location and expressed pericyte markers.
3.2. Adipocyte progenitors in adult adipose tissue
3.2.1. Mesenchymal stem cells
Mesenchymal stem cells (MSC) are postnatal progenitorswithmulti-
ple lineage potential and can be found in adipose tissue, bone marrow,
and other connective tissues [53]. MSC that reside in adipose tissue are
generally believed to be a principal source for adipocytes during postna-
tal growth and maintenance of adipose tissue [54]. Numerous studies
have isolated subpopulations of SVC and identiﬁed reliable cell surface
markers that can be used to enrich highly adipogenic subpopulations
(see review [54]). Among those studies, Rodeheffer et al. identiﬁed
Lin-CD29+CD34+Sca-1+CD24+ cells (CD24+ cells) as cells that
can reconstitute a functional epididymal fat pad when transplanted
into lipodystrophic mice [55]. CD24+ cells are relatively rare (0.08% of
SVC), yet have a remarkable capacity for self-renewal and can form a
functional organ with a limited number of cells. In subsequent studies,
these investigators conﬁrmed that all adipocyte progenitors express
platelet-derived growth factor receptor alpha (PDGFRα) [56], and
these cells can be further subdivided into CD24+ and CD24− fractions.
CD24 expression in PDGFRα cells appears to reﬂect the state of
adipogenic commitment, since CD24− PDGFRα cells are unable to form
functional WAT in the adipogenic environment of a lipodystrophic
mouse, yet do give rise to adipocytes at an ectopic site after transplanta-
tion. The PDGFRα+CD24− cells observed by the Rodeheffer [57] and
Granneman labs [56] appear to be highly similar, if not identical, popula-
tion of lineage-committed progenitors. This indicates that CD24+ cells
may be early-stage stem cells (i.e., long-term reconstituting stem
cells), and can give rise to lineage restricted adipogenic progenitors
(i.e., short-term reconstituting stem cells). In line with this observation,
subpopulations ofMSC in adult adipose tissue have been reported to ex-
press the multipotency markers OCT4 and telomerase [58]. Additional
studies, such as global transcriptome analysis of the CD24+ and
CD24− populations might identify additional markers of adipose
stem cells. Long-term reconstituting stem cells in other tissues often oc-
cupy a specialized niche that is important for ensuring stemness. How-
ever, it is presently unknownwhether such a specialized stem cell niche
exists within AT.
Although immunotyping studies have identiﬁed potential adipocyte
progenitor markers, genetic or chemical tracing is required to demon-
strate lineage potential in vivo [59]. Taking advantage of inducible
Cre-LoxP technology, we have identiﬁed cells in WAT that are capableof becoming BA or WA, depending on inductive signals [56]. These
cells express the surface markers CD34+Sca1+ PDGFRα+ cells
(PDGFRα+cells) and have a unique dendritic morphology. Although
these cells are often found in the perivascular region, they are negative
for pericyte markers and thus are distinct from developmental adipo-
cyte progenitors. The morphology, localization, and immunophenotypes
of PDGFRα+ cells are strikingly similar to adipogenic CD34+ cells in
human adipose, which also do not express pericyte markers [60]. Inter-
estingly, PDGFRα+ cells isolated from various depots exhibit similar
adipogenic behavior in vitro, yet PDGFRα+ cells in gonadal WAT are
much more prone to be activated by β3-AR stimulation and high fat
diet (HFD). These observations suggest that extrinsic cues from the AT
microenvironments might be important in depot-speciﬁc progenitor
recruitment in vivo.
3.2.2. Endothelial origin
The close temporal–spatial association between angiogenesis and
adipogenesis suggests that adipocytes may have endothelial origins;
however, whether adipocytes arise from the endothelium or its under-
lying mesenchyme has long been a matter of debate. Recent lineage
tracing of VE-cadherin expressing cells [61] suggests a contribution of
endothelial lineages to WA and BA. In addition, the endothelial cells
expressed a preadipocyte determination marker, ZFP432 [62], although
ZFP432 is expressed in numerous cell types. Adipocytes derived from
VE-cadherin+ progenitors may represent a subpopulation, as they do
not appear to be uniformly distributed throughoutWAT pads. In this re-
gard, committed endothelial cells (CD31+CD34+) from dissociated
AT are not adipogenic in vitro [63,64], and the original characterization
of VE-cadherin Cre mouse model showed little, if any, contribution of
these progenitors toWAT [65]. This discrepancymay be due to the tech-
nical difﬁculty of discriminating adipocytes from surrounding endothelial
cells, particularly when the lacZ reaction product is used as a reporter. To
address controversies, a recent study used amembrane-targeted ﬂuores-
cent reporter line, and demonstrated that endothelial cells, marked by
either Cdh5 (VE-cadherin) or Tie2 promoter activation, do not contribute
to adipogenesis during normal development and HFD feeding [57].
Alternatively, MSC in adipose tissue could be common progenitors for
endothelial cells and adipocytes, as SVC can differentiate into endothe-
lial cells in vitro [66,67] and in vivo [68].
3.2.3. BM-derived hematopoietic progenitors
Several studies indicate that circulating hematopoietic progenitors
derived from bone marrow (BM) can participate in adipogenesis
[69–71]. Genetic lineage tracingwith LysM-Cre indicates that adipogenic
progenitors are derived from the myeloid lineage [69] and BM-derived
progenitors contribute to adipogenesis in a sex- and depot-speciﬁc fash-
ion [72]. However, transplantation experiments [73] and genetic
tracing with Tie2 and Vav1-reporter lines failed to conﬁrm a hemato-
poietic contribution to adipogenesis during normal development
and high fat feeding [57]. Nonetheless, compared to conventional
adipocytes, BM-derived adipocytes have decreased expression of
genes involved in mitochondriogenesis and lipid metabolism, and
increased expression of pro-inﬂammatory markers [69]. Surprisingly,
expression of adiponectin and leptin is nearly absent in these cells. This
unique molecular phenotype suggests that BM-derived adipocytes
may be deleterious to metabolic health, and certainly warrant fur-
ther investigation.
3.3. Potential adipocyte progenitor niches
Stem cells typically reside in specialized anatomical locations, known
as stem cell niches, where neighboring cells and cues from the microen-
vironment maintain quiescence or trigger activity [74–76]. The stem cell
niche may be compartmentalized into distinct domains that enhance
dormancy, or provide cues for proliferation and differentiation [75,77].
Asmentioned above, preadipocytes have been localized to a perivascular
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the cell types and extrinsic signals that balance quiescence and recruit-
ment of progenitors are currently unknown. It is important to note that
the vast majority of cells in AT are not mature fat cells [81,82], but rather
are a dynamic mixture of cellular and non-cellular elements, including
progenitors, resident/recruited immune cells, ﬁbroblasts, blood vessels,
lymphatic vessels, peripheral nerves, and the extracellular matrix
(ECM). While growing evidence suggests roles for these elements
in progenitor recruitment and adipocyte function, the mechanistic
details are scant. Therefore, in this section, we will provide a brief over-
view of the cell types and niche factors that may be involved in adipocyte
progenitor recruitment. We also summarize the potential contribution of
pathologic remodeling of AT to disease states.
3.3.1. Adipose tissue macrophages
Adipose tissue macrophages have been intensively investigated as a
crucial cell type that affects themetabolic and endocrine functions of AT
[83,84].Macrophages have been classiﬁed into subpopulations based on
functional phenotypes [85]. Classically-activated M1 macrophages are
associated with immune defense and pro-inﬂammatory responses,
whereas alternatively-activatedM2macrophages are involved in tissue
repair and restoration [86]. The M1/M2 classiﬁcation has been largely
established by the in vitro characterization of mouse macrophages,
and it is important to emphasize that the in vivo polarization status of
AT macrophages exists on a dynamic continuum [86,87].
Interestingly, macrophages are believed to have trophic effects on
AT development [88,89]. Depletion of macrophages [89] or ablation
of macrophage colony stimulating factor impairs adipogenesis [90].
Macrophage-conditioned medium can inhibit preadipocyte apopto-
sis and promote survival in a PDGF-dependent manner [91]. In addi-
tion, macrophages are a major source of angiogenic factors and can
indirectly mediate AT expansion [92]. However, the speciﬁc effects
of macrophages on in vivo adipocyte progenitor activation have not
been investigated.
Pro-inﬂammatory M1 macrophages accumulate in AT during obesi-
ty [93] and thereby promote insulin resistance [94]. In contrast, polari-
zation of macrophages toward alternative activation preserves insulin
sensitivity via a PPARγ-dependent mechanism [95,96]. Additionally, a
recent study found that AT M2 macrophages secrete catecholamines,
which increase catabolism and sustain thermoregulatory functions dur-
ing cold exposure [97]. Alternatively-activated macrophages may also
prevent the adverse effects of excessive free fatty acid efﬂux during
weight loss by suppressing lipolysis [98].
3.3.2. Vasculature
Mounting data suggest that angiogenesis and adipogenesis are
tightly coupled during development [25,89,99] and postnatal fat expan-
sion [92,100–102]. In vitro studies suggest that signals derived from
surrounding vascular units directly inﬂuence preadipocyte proliferation
and differentiation. For example, Hutley et al. isolated macrovascular
endothelial cells and preadipocytes from human AT, and found that
conditioned media from endothelial cell cultures promote proliferation
of preadipocytes [103], whereas ECM obtained from rat AT-derived
endothelial cell cultures enhances differentiation of preadipocytes
[104]. However, the vascular-derived signals involved remain poor-
ly characterized.
Antiangiogenic reagents have been investigated as potential anti-
obesity therapies. Pharmacological inhibition of angiogenesis reduces
fat mass in obese mouse models [101,105]. However, the consequences
of modulating angiogenic activity appear to vary based on context.
Gain of function studies show that overexpression of VEGFA improves
metabolic proﬁles and prevents tissue dysfunction during the early
phase of diet-induced obesity [102]. In contrast, reducing vascularization
in established obesitymay improvemetabolic outcomes by inducing ap-
optosis in dysfunctional adipocytes [102].3.3.3. Innervation
The sympathetic nervous system plays an important role in regulat-
ing fatty acid mobilization and blood ﬂow in AT (reviewed in [106]). In
addition, adipocyte cellularity appears to be under sympathetic neuronal
control. Chemical sympathectomy or surgical denervation increases pro-
liferation and differentiation ofWAprogenitors [107–110], whereas sen-
sory denervation has no effect [107]. Consistent with in vivo ﬁndings,
physiological concentrations of norepinephrine inhibitWA preadipocyte
proliferation in vitro [111]. In contrast,α2 adrenergic receptor activation
induces proliferation of cultured preadipocytes [112], and upregulation
of α2 adrenergic receptors may be involved in denervation-induced ad-
ipocyte hypertrophy [110].
It is well known that adrenergic stimulation triggers the prolifera-
tion and differentiation of BA in classical BA depots [113], and in vitro
studies suggest that this effect is mediated by β1-AR [114]. Interesting-
ly, selective agonists of β3-AR have no effect on progenitor recruitment
in classic BA [56]. In contrast, β3-AR agonists can increase proliferation
and differentiation of BA progenitors in gonadalWAT and, to a lesser ex-
tent, in subcutaneousWAT [56]. It seems likely that these effects are in-
directly mediated by effects on mature fat cells, since β3-AR are not
expressed by preadipocytes. A recent study has demonstrated that deﬁ-
ciency of BAT created by genetic or surgical manipulation increased
sympathetic tone in WAT and contributed to the recruitment of BA in
WAT [115]. One intriguing questionwould bewhether de novo BA gen-
eration from progenitor proliferation is involved in this compensatory
browning of WAT driven by augmented sympathetic innervation.
3.3.4. Extracellular matrix (ECM)
The extracellular matrix (ECM) is an obligatory component of the
adipose tissue stroma that provides structural support and biochemical
signals to maintain proper AT function. Importantly, physical and bio-
chemical elements of ECMcan directMSC lineage speciﬁcation, prolifer-
ation, and differentiation (reviewed in [116]). Adipocyte progenitors
play an important role in ECM remodeling during development. Nu-
merous studies have documented changes in the abundance and com-
position of ECM produced by preadipocytes during differentiation
(reviewed in [117,118]). For example, differentiating preadipocytes
rapidly upregulate expression of collagen IV and various laminin com-
plexes, which remain high throughout the differentiation [119]. On
the other hand, ﬁbronectin expression decreases during adipocyte dif-
ferentiation in vivo [120] and in vitro [121]. Together, these ﬁndings
suggest that ECM conﬁguration undergoes a transition from a ﬁbrillar
to a laminar structure to accommodate adipocyte growth and fat stor-
age [118].
ECM degrading enzymes also play a crucial role in modifying ECM
structure and creating a permissive environment for tissue growth/
remodeling. The proteolytic system includes ﬁbrinolytic enzymes
and numerous matrix metalloproteinases (MMP) that affect AT de-
velopment (reviewed in [122]). For example, genetic inactivation of
MMP3 enhances hyperplastic and hypertrophic expansion of AT during
HFD feeding [123,124]. Knockout of MMP3 also accelerates develop-
ment of mammaryWAT [125]. Inhibition of MMP2 andMMP9 by phar-
macologic reagents or neutralizing antibodies reduces preadipocyte
differentiation in vitro [126,127]. General pharmacological inhibition
of MMP activity decreases the AT mass of mice fed a HFD [128], al-
though interpretation of pharmacological inhibition studies is compli-
cated by the fact that broad-spectrum inhibitors can affect multiple
MMP subtypes and other proteolytic enzymes.
While the aforementioned in vivo and in vitro studies support in-
volvement of multiple MMPs in adipogenesis under various conditions,
MT1-MMP seems to play an especially important role. WAT develop-
ment is not adversely affected by knockout of MMP2, MMP9, or MMP3
[129]; however, ablation ofMT1-MMPproduces a lipodystrophic pheno-
type [129]. MT1-MMP is a membrane-tethered collagenase that de-
grades pericellular type 1 collagen, which is abundantly expressed in
both undifferentiated and mature AT [129]. Interestingly, MT1-MMP
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from MT1-MMP null mice readily differentiate in 2D-culture condition
upon adipogenic induction, but not when restricted by a 3D-collagen
gel scaffold. Similarly, transplanted preadipocytes lacking MT1-MMP
fail to become adipocytes in wild type recipient mice.
Dysregulation of ECM synthesis and turnover can lead to ﬁbrosis and
dysfunction of AT. Fibrosis is a common pathophysiological response to
chronic injury in which excess accumulation of ﬁbrotic ECM distorts tis-
sue architecture and impairs the function of parenchymal cells [130].
During obesity, metabolically-challenged AT increases ﬁbrous collagen
production and upregulates related genes [84,131,132]. Consequently,
increased ECM stiffness restricts adipocyte hypertrophy, and may cause
ectopic fat accumulation [131]. Deletion of collagen VI in ob/ob mice en-
hances hypertrophic expansion and improves metabolic proﬁle [131].
Adipose tissue macrophages, which are recruited in obese states, con-
tribute to ﬁbrosis by stimulating ﬁbroblast ECM synthesis [133,134]. In
addition, local hypoxia may contribute to ﬁbrosis via HIF1α dependent
mechanisms [132]. Although ECM-producing ﬁbroblasts are a keymedi-
ator of pathogenesis of ﬁbrosis, the cellular origin of adipose tissue ﬁbro-
blasts is not known.However, since PDGFRα+cells have been identiﬁed
as adipo-ﬁbrogenic progenitors in muscle [135–138], it is likely that
these cells can become ﬁbrogenic under pathological conditions.
4. Adipose tissue plasticity
Adipocytes are replenished throughout an organism's life, and are
dynamically regulated in terms of their numbers, size, and metabolic
characteristics. Adipocyte progenitors are activated during homeostatic
turnover and hyperplastic expansion, and can also participate in cata-
bolic remodeling, or “browning” of AT. Certain differentiated adipocytes
can also contribute to AT plasticity by undergoing a phenotypic switch
between anabolic and catabolic states. Here, we review recent work
that highlights the range of cellular and metabolic phenotypes that
exist in typical “white” adipose tissue depots, and points to possible
avenues for engineering beneﬁcial phenotypes in vivo.
4.1. Control of adipocyte cellularity
Adipocyte cellularity is determined early in life [139–142], yet there
is clear propensity for cell renewal throughout the lifetime. Metabolic
labeling studies with deuterium indicate that the half-life of adipocytes
in humans is about 6 months, representing a turnover rate of 60% per
year [143]. On the other hand, 14C decay analysis by Spalding et al.
found that turnover is much less, with adipocytes replaced on average
every 8.3 years. Interestingly, turnover is independent of body mass
index, further suggesting that adipocyte number is determined at an
early age and is relatively static in adulthood [141]. Despite these dis-
crepancies in estimates of adipocyte lifetime, the cells within AT clearly
turnover in the adult, and this phenomenon might be exploited for
therapeutic purposes. Prior to the 1960s, it was thought that adipocytes
were static in the rodent, but recent estimates indicate that mouse adi-
pocytes are turned over every six months, with 1–5% of adipocytes
being replaced every day [144].
Whether AT expansion occurs by adipocyte hypertrophy or hyperpla-
sia depends upon anatomic location in humans and rodents [51,145,146].
The in vitro proliferation potential of progenitors correlates with depot-
speciﬁc adipocyte hyperplasia in response to a high fat diet [51,145].
These data agree with human studies in which overfeeding increased
lower-body fat depots by hyperplasia, whereas abdominal fat in-
creased by hypertrophy [146]. Adipogenesis is thought to occur
once hypertrophied fat cells reach a critical size [147]. This process
involves adipocyte death [141] and the proliferation of progenitors,
followed by the appearance of smaller adipocytes [148]. Inherent
differences in the ability of depots to expand by proliferation might be
important in determining metabolic outcomes, considering the poor
metabolic proﬁle associatedwith excessive visceral fat in humans [149].4.2. Plasticity of adipocyte phenotype
Adipocytes within WAT depots have a remarkable capacity to alter
their metabolic phenotype from typical WA to those resembling BA
[150–152]. This phenomenon has been referred to as “browning” and
is readily induced by cold exposure and β-adrenergic stimulation [151].
Browning has been extensively demonstrated only in small mammals,
and the extent to which this occurs in humans is an open question. Typ-
ically, browning involves the appearance of multilocular adipocyte clus-
ters that are dispersed among unilocular WA [153,154]. The browning
phenomenon varies among WAT depots and is strongly inﬂuenced by
numerous genetic factors [155,156]. These multilocular, UCP1+ adipo-
cytes were initially called “convertible,” since the phenotype can be in-
duced from existing unilocular UCP1− cells without cell proliferation
[157–159]. Although recent groups have named these cells “brown in
white” (BRITE) [160] or beige [39], it is not clear whether these various
designations refer to the same cell type [56,150,160,161]. Indeed, limited
genetic tracing experiments suggest that there may be heterogeneity
among cells types that are capable of browning [56,162].
Analyses of adipocyte ultrastructure suggest that the WA/BA transi-
tion can be bidirectional [159,163]. Interestingly, those depots that are
most susceptible to browning, such as retroperitoneal and inguinal fat
pads, are densely populated with multilocular UCP1+ adipocytes
early in development, and these cells likely revert to a WA-like pheno-
type in adulthood [161,164,165]. BA in WAT can also be derived from
the recruitment of progenitors, which appears to be the major mode
of browning of the gonadal fat depot [56]. Early work from our group
established that BA in abdominal WAT can arise from new cellular pro-
liferation [150].More recently, our group utilized lineage tracing studies
to demonstrate that greater than 90% of BA in abdominal WAT arise
froma subpopulation of CD34+cells that express PDGFRα [56]. The ap-
pearance of these inducible BA is dependent upon the stimulus, as a
dose of β3-AR agonist that promotes fatty acid-induced inﬂammation
in WAT reduces their appearance [166–168]. In addition, prospective
analyses have identiﬁed progenitor cells that respond to activation of
the cyclooxygenase 2/prostaglandin pathway [16] and give rise to BA
both in vitro and in vivo [160,162].
While some BA-like adipocytes express UCP1 [153,163], UCP1 is not
essential for the chronic thermogenic actions of β3-AR agonists, or for
the appearance of multilocular fat cells in white fat depots [163,169].
These BA-like cells, which are found mostly in abdominal (gonadal)
fat pads, are multilocular and have abundant mitochondria, yet clearly
lack UCP1 [163]. UCP1−multilocular adipocytes exhibit elevated met-
abolic rate [170] and PPARα-dependent upregulation of fatty acid oxi-
dation [166].
5. Pathological remodeling of adipose tissue
Substantial evidence suggests that adverse consequences of obesity
have their origins in the pathological remodeling of AT [84]. Numerous
studies demonstrate that obesity in mice and man is associated with
elevated expression of inﬂammatory cytokines, adipocyte death, and
recruitment of inﬂammatory macrophages [171–174]. Importantly,
genetic and/or pharmacological approaches that reduce AT inﬂamma-
tion restore anabolic functions and improve systemic insulin action
[171,175]. Here we brieﬂy summarize mechanisms of inﬂammation
in obesity; recent reviews have covered this topic in greater depth
[176,177].
Chronic overnutrition increases the occurrence of hypertrophic fat
cells, which upon reaching a critical size become distressed and under-
go necrosis/apoptosis. Adipocyte cell death recruits macrophages,
which surround and ultimately remove the dead fat cells [174]. These
adipocyte clearance structures are often called “crown-like structures”
(CLS) which describe their appearance in histological sections. The for-
mation of these CLS further triggers a local inﬂammatory response that
impairs the functioning of nearby adipocytes [178,179]. Inﬂammation
Fig. 1. Adipocyte receptors that have been proposed to promote the browning of white fat
or maintenance of a brown adipocyte (BA) phenotype. β3-Adrenergic receptor (β3-AR)
which signals through protein kinase A (PKA) to phosphorylate (P) and activate transcrip-
tion factors such as cAMP response element binding protein (CREB). β3-ARs also activate
p38 which phosphorylates ATF2 to promote the transcription of genes such as PGC1α
and UCP1. In parallel, β3-ARs stimulate lipolysis by adipose triglyceride lipase (ATGL) and
hormone sensitive lipase (HSL). Free fatty acids (FFA) mobilized by these lipases activate
peroxisome proliferator-activated receptor (PPARα) and PPARδ (not shown) to promote
the expression of BA genes. Natriuretic peptides (NP) bind natriuretic peptide receptors
(NPR) and activate protein kinase G (PKG). In addition, bone morphogenetic protein
(BMP8b) and BMP7 signal through p38 by unknownmechanisms (dashed line). Fibroblast
growth factor 21 (FGF21) produced by the liver and in brown adipose tissue, acts through
the receptor FGF1 and scaffold βKlotho to activate ERK1/2 and promote a BA phenotype
through unknown pathways. Transient receptor potential cation channel subfamily M
member 8 (TRPM8), which is activated by menthol, promotes thermogenesis in BAT in a
PKA-dependent manner. Thiazolidinediones (TZDs) activate PPARγ, which through
PRDM16 and the deacetylase sirtuin1 (SirT1), promote the browning of white fat. Finally,
the hormone irisin, secreted from muscle, binds a yet unknown receptor to promote the
appearance of BA by signaling through a PPARα dependent pathway.
363Y.-H. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 358–369disrupts the balance between fatty acid storage and mobilization and
contributes to the production of lipid mediators that impair insulin sig-
naling [180]. In addition, AT ﬁbrosis promotes inﬂammatory responses
and exacerbates insulin resistance in fat tissue [132]. Notably, reducing
the constraints of the ECM increases fat cell expansion and improves
whole body metabolism [131]. In humans with obesity, the exhaustion
[181] and impaired commitment of adipocyte progenitors [182,183]
may also limit beneﬁcial AT expansion.
Aging is associated with deleterious alterations in AT. Preadipocytes
from aged rats [184] and older individuals [185] have reduced ability to
proliferate and differentiate. The diminished ability of aged progenitors
to replicate might be due to cellular senescence, which can be observed
in vitro [186] and in vivo [187,188]. Importantly, genetic approaches
that reduce senescence improve insulin sensitivity [187], and removal
of senescent cells improves age-related loss of AT [188]. Aging in mice
is also associated with reduced adrenergic tone and loss of brown adi-
pocytes in subcutaneous WAT [189].
6. Therapeutic remodeling of adipose tissue
As mentioned in the Introduction, one means of addressing the ad-
verse metabolic consequences of obesity is to increase the capacity of
AT to buffer excess energy. PPARγ is themaster regulator of adipogenesis,
and its activation with thiazolidinediones (TZDs) induces metabolic and
cellular remodeling that improves the ability of AT to sequester fatty
acids. On the other hand, β3-AR agonists improve metabolism in rodent
models of type 2 diabetes by expanding the ability of brown and white
adipose tissues to oxidize fatty acids in situ, and thereby prevent systemic
lipotoxicity. Although β3-AR agonists have not been successful in
humans [190], their experimental use in rodent models has provided
new information on the mechanisms of AT plasticity. This new apprecia-
tion of AT plasticity has sparked an explosion of work that is likely to lead
to new means of expanding beneﬁcial phenotypes in vivo.
6.1. Peroxisome proliferator-activated receptor γ
PPARγ is a nuclear receptor that is highly expressed in AT [191] and
is a master regulator of adipogenesis [192] (reviewed in [193]). PPARγ
is selectively activated by a class of anti-diabetic agents, the TZDs
[193]. In humans, TZDs ameliorate insulin resistance, increase peripher-
al glucose utilization and improve serum lipid levels [194]. The thera-
peutic actions of TZDs in rodents are mediated by several molecular
targets in multiple tissues [195–197]; nonetheless, activation of the AT
PPARγ appears to play a central role [198,199]. TZDs improve the ability
of AT to sequester excess energy by upregulating the expression of
genes involved in de novo lipogenesis and fatty acid uptake [200].
TZDs promote fat storage preferentially in subcutaneous WAT without
increasingwhole body energy expenditure [201]. TZDs also improve in-
sulin sensitivity by improving adipokine proﬁles [202]. Adiponectin
levels are reduced in obesity [203] and are correlated with insulin sen-
sitivity [202]. TZD treatment rapidly increases adiponectin levels [204],
and in mice, these effects involve activation of AMP kinase by
adiponectin [205]. TZDs also activate PPARγ in certain lipid-sensing reg-
ulatory T-cells that regulate the inﬂammatory state of AT [195]. Similar-
ly, TZDs suppress the expression of pro-inﬂammatory genes [206,207]
and promote the recruitment of anti-inﬂammatory tissue-remodeling
macrophages [208]. Consistent with an adipocentric view, transgenic
overexpression of PPARγ in AT mimics the systemic delivery of TZDs
by reducing inﬂammation and improving adipokine proﬁles [199]. In
addition, new work demonstrates that the crosstalk between PPARγ
and the growth factors FGF1 and FGF21 is critical for the actions of
TZDs in maintaining healthy AT [209,210].
TZDs might impart therapeutic effects by increasing catabolic
functions of WAT (Fig. 1). TZDs promote fatty acid re-esteriﬁcation
and futile cycling [211], which are energetically-demanding process-
es that increase mitochondrial biogenesis, energy expenditure, andfatty acid oxidation [212]. The clinical responsiveness of diabetic pa-
tients to TZDs is correlatedwith improvements inmitochondrial gene ex-
pression and reductions in inﬂammation [213]. In vitro, PPARγ agonism
promotes the appearance of UCP1+ brown adipocytes in a population
of EWAT-derived progenitors [160]. The mechanisms by which PPARγ
agonism facilitates the appearance of brown adipocytes include stabiliza-
tion of PRDM16 [214], suppression of WA-speciﬁc genes [215], and
SirT1-dependent deacetylation of PPARγ [216]. Interestingly, the binding
of PPARγ to genes that determine brown or white adipocyte expression
patterns is depot-dependent, suggesting that the ability of TZDs to pro-
mote a brown or white phenotype is epigenetically pre-programmed
[217]. Whether TZDs promote recruitment and activation of brown adi-
pocytes in humans is not known; however, PPARγ agonism promotes
characteristics of brown adipocytes in a human pre-adipocyte cell line
[218].
6.2. β3-Adrenergic receptors
In rodents, physiological or pharmacological stimulation of β3-ARs
rapidly activates nonshivering thermogenesis in brown fat [219]. Al-
though the thermogenic actions of β3-AR agonists have been attributed
to activation of brown fat, activation of both BAT andWAT is required for
a full thermogenic response [154]. The anti-diabetic effects of β3-AR ag-
onists require chronic treatment [219], and are correlatedwith dramatic
remodeling of WAT [150,220]. Interestingly, improvement in insulin
sensitivity can be seen prior to changes in body weight [221].
The mechanisms bywhich β-ARs enhance the catabolic character of
brown fat and the appearance of BA in WAT are not completely under-
stood, but are complex and involve synergy among various signaling
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the browning of white fat, such as activation of p38 [223] and cAMP
response element-binding protein [224], likely lie downstream of the
cAMP/protein kinase A signaling pathway [156]. One critical factor
that is upregulated by PKA is PGC1α, transcriptional co-activator of nu-
clear receptors that is necessary for themaximal induction ofmitochon-
drial biogenesis and UCP1 expression [225–227]. In addition, PPARα
and type 2 diodinase have been identiﬁed as genes associated with
maximal induction of UCP1 expression in WAT depots [228].
In addition to the direct activation of transcription factors, PKA also
triggers lipolysis, which provides ligands for the nuclear receptors
PPARα and PPARδ. Dynamic imaging shows that ligands for PPARα and
PPARδ are produced within minutes of activating lipolysis and function
tomatch theoxidative capacitywith the supply of fatty acids [229].More-
over, knockout of hormone sensitive lipase or PPARα delays induction of
genes involved in mitochondrial biogenesis and fatty acid oxidation dur-
ing β3-AR agonist treatment [220,230]. Similarly, overexpression of adi-
pose triglyceride lipase (ATGL) enhances the catabolic phenotype of
white fat, while AT-speciﬁc deletion of ATGL promotes awhite fat pheno-
type in BAT, with reduced expression of PPARα target genes [231].While
these data indicate that intracellular lipolysis supports a catabolic pheno-
type, excessive mobilization of fatty acids can trigger inﬂammation in
WAT [98,150,167,220,230].
6.3. Other factors that promote a BA phenotype
The role ofβ-ARs in browning ofWAThas been known for some time,
but recent evidence demonstrates that the appearance of BA andmainte-
nance of a BAprogramcanbe induced by other hormones, cytokines, and
growth factors (Fig. 1). Bostrom et al. demonstrated that a muscle-
derived cytokine, irisin, is increased by exercise and induces the brow-
ning of subcutaneous AT [232]. Interestingly, the induction of BA genes
by irisin involves activation of PPARα; however,whether irisin has a sim-
ilar role of improving metabolic outcomes in humans is a matter of de-
bate [233,234]. BMP7, a morphogen important for development, can
promote the differentiation of a population of preadipocytes toward BA
and is necessary for the formation of BAT,while overexpression increases
energy expenditure [162]. BMP7 also increases mitochondrial activity in
mature brown adipocytes [235]. Additionally, BMP8b acts directly on
brown fat and via the central nervous system to increase thermogenic
activity [236]. Fibroblast growth factor 21 (FGF21) has been suggested
to drive BAT-dependent thermogenesis after birth [237] and contribute
to browning of white fat in adults [238,239]. The metabolic effects
of FGF21 require signaling through FGFR1 and the scaffold βKlotho
[240–242]. Interestingly, cold-induced elevation of circulating FGF21
levels is associated with thermogenesis in humans [243]. In addition,
transient receptor potential cation channel subfamily M member 8
(TRPM8), the cold-sensing receptor that is activated by menthol, is
expressed in BAT and promotes UCP1-dependent thermogenesis [244].
The browning ofWAT can also be induced in transgenic animals that ex-
press transcription factors such as PRDM16 [245], RIP140 [246], pRB and
p107 [247], and FoxC2 [248]. Finally, cardiac-derived natriuretic peptides
(NP) [249], which are potent activators of lipolysis in human fat cells, can
promote the browning ofwhite fat and thermogenesis inmice, and drive
increased respiration in human fat cell cultures [250]. Importantly, NP
treatment stimulates lipolysis and increases lipid oxidation and energy
expenditure in humans [249,251]. An important question to address is
whether natriuretic peptides enhance energy expenditure by acting on
brown fat, skeletal muscle, or both [252].
7. Concluding remarks
The mechanistic study of cellular and metabolic plasticity of AT will
raise newopportunities in treating obesity and its relatedmetabolic dis-
orders. Understanding the signals that determine progenitor fate may
lead to new therapeutic approaches. For example, PDGFRα progenitorsinWAT appear to be capable of differentiating intoWA, BA, or ﬁbroblasts.
Clearly, understanding the cues that drive the fate of this population could
be key to preserving metabolically healthy WAT. Interestingly, recent
evidence suggests that TZD-enhanced insulin sensitization is associated
with the appearance of new adipocytes in muscle [213]. Thus, an under-
standing of how TZDs target speciﬁc progenitor populations is also
important.
The metabolic improvements associated with activation of BAT in
rodents have led to the suggestion that human BAT (hBAT) might be
developed as a therapeutic target. Agonists of β3-ARs have potent
anti-obesity and anti-diabetes effects in rodent models [219,253].
However, β3-AR expression is low in human AT, and selective
β3-AR agonists have not been proven effective in man [190]. Thus
far, indirect (ephedrine) and direct (isoproterenol) sympathomi-
metics have also failed to activate hBAT at doses that raise the meta-
bolic rate [254–256]. Clearly, additional means other than cold stress
will be needed for BAT activation to be a practical target in humans.
Since fatty acids are necessary and sufﬁcient to drive brown fat ther-
mogenesis [257], promoting lipolysis [229,231,258] by mechanisms
that are parallel or distal to adrenergic receptors may be effective.
Whether the reported amounts of BAT in humans are sufﬁcient to have
an effect on whole energy expenditure is a matter of debate. Direct mea-
sures of bloodﬂowandO2metabolism in hBAT during cold stress indicate
that the amount of activity of human BAT would need to increase by ap-
proximately 50 times to impact energy balance [259]. Increasing the
amount of BAT or BA in WAT could be accomplished by manipulating
transcription factors such as PRDM16 or Rb/p107; however, the critical
roles of these factors in organogenesis and transformation will need to
be considered [260,261]. Targeting microRNA (miRNA) that modulates
brown fat differentiation [262,263] or browning of white fat [264] is an
additional possibility. Others have suggested that fat transplants [265],
and inducible pluripotent stem cells [266,267] could be used to expand
brownAT in vivo.However, BAT is not simply a single cell type, but a com-
plex organ that requires a vasculature to supply oxygen and energy to be
burned and a means of thermogenic activation. Future studies are re-
quired to address these hurdles; however, given recent advances in
knowledge, targeting adipose tissue plasticity seems to be an increasingly
feasible avenue for therapeutic intervention.
Acknowledgements
This work was supported by National Institutes of Health grants
RO1DK076629 and RO1DK62292. E.P. Mottillo was supported by the
Canadian Institutes of Health Research Doctoral Research Award
MDR-214349. We thank Rachel Granneman for editorial assistance.
References
[1] R.H. Unger, Lipotoxic diseases, Annu. Rev. Med. 53 (2002) 319–336.
[2] S. Cinti, The adipose organ: morphological perspectives of adipose tissues, Proc.
Nutr. Soc. 60 (2001) 319–328.
[3] R. Unger, P. Scherer, Gluttony, sloth and the metabolic syndrome: a roadmap to
lipotoxicity, Trends in endocrinology and metabolism: TEM 21 (2010) 345–352.
[4] A. Pal, T.M. Barber,M. Van deBunt, S.A. Rudge, Q. Zhang, K.L. Lachlan, N.S. Cooper, H.
Linden, J.C. Levy,M.J.Wakelam, L.Walker, F. Karpe, A.L. Gloyn, PTENmutations as a
cause of constitutive insulin sensitivity and obesity, N. Engl. J. Med. 367 (2012)
1002–1011.
[5] R.A. Hegele, T.R. Joy, S.A. Al-Attar, B.K. Rutt, Thematic review series: adipocyte
biology. Lipodystrophies: windows on adipose biology and metabolism, J. Lipid
Res. 48 (2007) 1433–1444.
[6] M.Y. Wang, P. Grayburn, S. Chen, M. Ravazzola, L. Orci, R.H. Unger, Adipogenic
capacity and the susceptibility to type 2 diabetes and metabolic syndrome,
Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 6139–6144.
[7] J.Y. Kim, E. van de Wall, M. Laplante, A. Azzara, M.E. Trujillo, S.M. Hofmann, T.
Schraw, J.L. Durand, H. Li, G. Li, L.A. Jelicks, M.F. Mehler, D.Y. Hui, Y. Deshaies, G.I.
Shulman, G.J. Schwartz, P.E. Scherer, Obesity-associated improvements inmetabolic
proﬁle through expansion of adipose tissue, J. Clin. Invest. 117 (2007) 2621–2637.
[8] D.O. Foster, M.L. Frydman, Nonshivering thermogenesis in the rat. II. Measure-
ments of blood ﬂowwith microspheres point to brown adipose tissue as the dom-
inant site of the calorigenesis induced by noradrenaline, Can. J. Physiol. Pharmacol.
56 (1978) 110–122.
365Y.-H. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 358–369[9] P.L. Thurlby, P. Trayhurn, The role of thermoregulatory thermogenesis in the
development of obesity in genetically-obese (ob/ob) mice pair-fed with lean
siblings, Br. J. Nutr. 42 (1979) 377–385.
[10] S.W. Ma, D.O. Foster, B.E. Nadeau, J. Triandaﬁllou, Absence of increased oxygen con-
sumption in brown adipose tissue of rats exhibiting “cafeteria” diet-induced thermo-
genesis, Can. J. Physiol. Pharmacol. 66 (1988) 1347–1354.
[11] L.P. Kozak, Brown fat and the myth of diet-induced thermogenesis, Cell Metab.
11 (2010) 263–267.
[12] J. Nedergaard, B. Cannon, The changedmetabolic worldwith human brown adipose
tissue: therapeutic visions, Cell Metab. 11 (2010) 268–272.
[13] E. Ravussin, J. Galgani, The implication of brown adipose tissue for humans,
Annu. Rev. Nutr. 31 (2011) 33–47.
[14] E. Ravussin, L.P. Kozak, Have we entered the brown adipose tissue renaissance?
Obes. Rev. 10 (2009) 265–268.
[15] J.R.S. Arch, β3-Adrenoceptor agonists: potential, pitfalls and progress, Eur. J.
Pharmacol. 440 (2002) 99–107.
[16] A. Vegiopoulos, K. Müller-Decker, D. Strzoda, I. Schmitt, E. Chichelnitskiy, A.
Ostertag, M.B. Diaz, J. Rozman, M. Hrabe de Angelis, R.M. Nüsing, C.W. Meyer, W.
Wahli, M. Klingenspor, S. Herzig, Cyclooxygenase-2 controls energy homeostasis
in mice by de novo recruitment of brown adipocytes, Science 328 (2010)
1158–1161.
[17] L.Z. Sharp, K. Shinoda, H. Ohno, D.W. Scheel, E. Tomoda, L. Ruiz, H. Hu, L. Wang,
Z. Pavlova, V. Gilsanz, S. Kajimura, Human BAT possesses molecular signatures
that resemble beige/brite cells, PLoS One 7 (2012) e49452.
[18] J. Wu, P. Bostrom, L.M. Sparks, L. Ye, J.H. Choi, A.H. Giang, M. Khandekar, K.A.
Virtanen, P. Nuutila, G. Schaart, K. Huang, H. Tu, W.D. van Marken Lichtenbelt, J.
Hoeks, S. Enerback, P. Schrauwen, B.M. Spiegelman, Beige adipocytes are a distinct
type of thermogenic fat cell in mouse and human, Cell 150 (2012) 366–376.
[19] S. Cinti, The adipose organ, Prostaglandins Leukot. Essent. Fatty Acids 73 (2005)
9–15.
[20] S. Gesta, Y.H. Tseng, C.R. Kahn, Developmental origin of fat: tracking obesity to
its source, Cell 131 (2007) 242–256.
[21] P. Wassermann, The Development of Adipose Tissue, American Physiological Society,
Washington, DC, 1965.
[22] G. Simon, Histogenesis, Handbook of Physiology, American Physiological Society,
Washington, DC, 1965.
[23] C.M. Poissonnet, A.R. Burdi, S.M. Garn, The chronology of adipose tissue appearance
and distribution in the human fetus, Early Hum. Dev. 10 (1984) 1–11.
[24] C.M. Poissonnet, A.R. Burdi, F.L. Bookstein, Growth and development of human
adipose tissue during early gestation, Early Hum. Dev. 8 (1983) 1–11.
[25] D.L. Crandall, G.J. Hausman, J.G. Kral, A review of the microcirculation of adipose
tissue: anatomic, Metabolic, and Angiogenic Perspectives, Microcirculation 4
(1997) 211–232.
[26] M. Ochi, T. Sawada, T. Hattori, Tritiated thymidine autoradiographic study on
postnatal development of epididymal adipose tissue in the normal mouse,
Anat Embryol (Berl) 177 (1987) 139–145.
[27] C. Pilgrim, DNA synthesis and differentiation in developing white adipose tissue,
Dev. Biol. 26 (1971) 69–76.
[28] S.P. Poulos, D.B. Hausman, G.J. Hausman, The development and endocrine functions
of adipose tissue, Mol. Cell. Endocrinol. 323 (2010) 20–34.
[29] C.M. Poissonnet, Growth and development of adipose tissue, J. Pediatr. 113 (1988)
1–9.
[30] M.R.C. Greenwood, J. Hirsch, Postnatal development of adipocyte cellularity in
the normal rat, J. Lipid Res. 15 (1974) 474–483.
[31] J. Kirtland, Changes in adipose tissue of the rat due early undernutrition
followed by rehabilitation. 3. Changes in cell replication studied with tritiated
thymidine, Br. J. Nutr. 43 (1980) 33–43.
[32] T.A.M. Harrington, Distribution of adipose tissue in the newborn, Pediatr. Res. 55
(2004) 437–441.
[33] B. Cannon, J. Nedergaard, Brown adipose tissue: function and physiological signiﬁ-
cance, Physiol. Rev. 84 (2004) 277–359.
[34] N. Billon, P. Iannarelli, M.C. Monteiro, C. Glavieux-Pardanaud, W.D. Richardson,
N. Kessaris, C. Dani, E. Dupin, The generation of adipocytes by the neural crest,
Development 134 (2007) 2283–2292.
[35] M. Bronner-Fraser, Neural crest cell formation and migration in the developing
embryo, FASEB J. 8 (1994) 699–706.
[36] E. Lorin, P. Olson, Soriano, PDGFRβ signaling regulates mural cell plasticity and
inhibits fat development, Dev. Cell 20 (2011) 815–826.
[37] L. Chang, L. Villacorta, R. Li, M. Hamblin, W. Xu, C. Dou, J. Zhang, J. Wu, R. Zeng, Y.E.
Chen, Loss of perivascular adipose tissue on peroxisome proliferator-activated
receptor-γ deletion in smoothmuscle cells impairs intravascular thermoregulation
and enhances atherosclerosis, Circulation 126 (2012) 1067–1078.
[38] J.A. Timmons, K. Wennmalm, O. Larsson, T.B. Walden, T. Lassmann, N. Petrovic,
D.L. Hamilton, R.E. Gimeno, C. Wahlestedt, K. Baar, J. Nedergaard, B. Cannon,
Myogenic gene expression signature establishes that brown and white adipo-
cytes originate from distinct cell lineages, Proc. Natl. Acad. Sci. USA 104 (2007)
4401–4406.
[39] P. Seale, B. Bjork, W. Yang, S. Kajimura, S. Chin, S. Kuang, A. Scime, S. Devarakonda,
H.M. Conroe, H. Erdjument-Bromage, P. Tempst, M.A. Rudnicki, D.R. Beier, B.M.
Spiegelman, PRDM16 controls a brown fat/skeletal muscle switch, Nature 454
(2008) 961–967.
[40] N. Gensch, T. Borchardt, A. Schneider, D. Riethmacher, T. Braun, Different autonomous
myogenic cell populations revealed by ablation of Myf5-expressing cells during
mouse embryogenesis, Development 135 (2008) 1597–1604.
[41] J. Sanchez-Gurmaches, C.-M. Hung, Cynthia A. Sparks, Y. Tang, H. Li, David A.
Guertin, PTEN loss in the Myf5 lineage redistributes body fat and reveals subsetsof white adipocytes that arise from Myf5 precursors, Cell Metab. 16 (2012)
348–362.
[42] N.D. Billon, Christian developmental origins of the adipocyte lineage: new insights
from genetics and genomics studies, Stem Cell Rev. 8 (2012) 55–66.
[43] C. Lepper, C.-M. Fan, Inducible lineage tracing of Pax7-descendant cells reveals
embryonic origin of adult satellite cells, Genesis 48 (2010) 424–436.
[44] H.G. Linhart, K. Ishimura-Oka, F. DeMayo, T. Kibe, D. Repka, B. Poindexter, R.J.
Bick, G.J. Darlington, C/EBPα is required for differentiation of white, but not
brown, adipose tissue, Proc. Natl. Acad. Sci. 98 (2001) 12532–12537.
[45] T. Tanaka, N. Yoshida, T. Kishimoto, S. Akira, Defective adipocyte differentiation
in mice lacking the C/EBP[beta] and/or C/EBP[delta] gene, EMBO J. 16 (1997)
7432–7443.
[46] J.A. Pospisilik, D. Schramek, H. Schnidar, S.J.F. Cronin, N.T. Nehme, X. Zhang, C.
Knauf, P.D. Cani, K. Aumayr, J. Todoric, M. Bayer, A. Haschemi, V. Puviindran, K.
Tar, M. Orthofer, G.G. Neely, G. Dietzl, A. Manoukian, M. Funovics, G. Prager, O.
Wagner, D. Ferrandon, F. Aberger, C.-c. Hui, H. Esterbauer, J.M. Penninger, Drosoph-
ila genome-wide obesity screen reveals hedgehog as a determinant of brown
versus white adipose cell fate, Cell 140 (2010) 148–160.
[47] A. Garg, Lipodystrophies: genetic and acquired body fat disorders, J. Clin. Endocrinol.
Metab. 96 (2011) 3313–3325.
[48] E.H. Jeninga, E. Kalkhoven, Central players in inherited lipodystrophies, Trends
Endocrinol. Metab. 21 (2010) 581–588.
[49] J. Capeau, J. Magre, M. Caron-Debarle, C. Lagathu, B. Antoine, V. Bereziat, O.
Lascols, J.P. Bastard, C. Vigouroux, Human lipodystrophies: genetic and acquired
diseases of adipose tissue, Endocr. Dev. 19 (2010) 1–20.
[50] S. Gesta, M. Blüher, Y. Yamamoto, A.W. Norris, J. Berndt, S. Kralisch, J. Boucher, C.
Lewis, C.R. Kahn, Evidence for a role of developmental genes in the origin of obesity
and body fat distribution, Proc. Natl. Acad. Sci. 103 (2006) 6676–6681.
[51] Y. Macotela, B. Emanuelli, M.A. Mori, S. Gesta, T.J. Schulz, Y.-H. Tseng, C.R. Kahn,
Intrinsic differences in adipocyte precursor cells from different white fat depots,
Diabetes 61 (2012) 1691–1699.
[52] W. Tang, D. Zeve, J.M. Suh, D. Bosnakovski, M. Kyba, R.E. Hammer, M.D. Tallquist,
J.M. Graff, White fat progenitor cells reside in the adipose vasculature, Science
322 (2008) 583–586.
[53] P. Bianco, P.G. Robey, P.J. Simmons, Mesenchymal stem cells: revisiting history,
Concepts, and Assays, Cell Stem Cell 2 (2008) 313–319.
[54] W.P. Cawthorn, E.L. Scheller, O.A. MacDougald, Adipose tissue stem cells meet
preadipocyte commitment: going back to the future, J. Lipid Res. 53 (2012)
227–246.
[55] M.S. Rodeheffer, K. Birsoy, J.M. Friedman, Identiﬁcation of white adipocyte progenitor
cells in vivo, Cell 135 (2008) 240–249.
[56] Y.-H. Lee, Anelia P. Petkova, Emilio P.Mottillo, James G. Granneman, In vivo identiﬁca-
tion of bipotential adipocyte progenitors recruited by β3-adrenoceptor activation and
high-fat feeding, Cell Metab. 15 (2012) 480–491.
[57] R. Berry, M.S. Rodeheffer, Characterization of the adipocyte cellular lineage in
vivo, Nat. Cell Biol. 15 (2013) 302–308.
[58] G. Lin, M. Garcia, H. Ning, L. Banie, Y.L. Guo, T.F. Lue, C.S. Lin, Deﬁning stem and
progenitor cells within adipose tissue, Stem Cells Dev. 17 (2008) 1053–1063.
[59] A. Van Keymeulen, A.S. Rocha, M. Ousset, B. Beck, G. Bouvencourt, J. Rock, N.
Sharma, S. Dekoninck, C. Blanpain, Distinct stem cells contribute to mammary
gland development and maintenance, Nature 479 (2011) 189–193.
[60] A. Bouloumie, P. Bourin, L. Casteilla, R. Dangelo, C. Fournier-Wirth, M. Maumus,
J.A. Peyraﬁtte, C. Sengenes, Native human adipose stromal cells: localization,
morphology and phenotype, Int. J. Obes. 35 (2011) 1141+.
[61] K.-V. Tran, O. Gealekman, A. Frontini, Maria C. Zingaretti, M. Morroni, A.
Giordano, A. Smorlesi, J. Perugini, R. De Matteis, A. Sbarbati, S. Corvera, S. Cinti,
The vascular endothelium of the adipose tissue gives rise to both white and
brown fat cells, Cell Metab. 15 (2012) 222–229.
[62] RanaK. Gupta, Rina J.Mepani, S. Kleiner, James C. Lo,Melin J. Khandekar, P. Cohen,A.
Frontini, Diti C. Bhowmick, L. Ye, S. Cinti, Bruce M. Spiegelman, Zfp423 expression
identiﬁes committed preadipocytes and localizes to adipose endothelial and
perivascular cells, Cell Metab. 15 (2012) 230–239.
[63] J.M. Gimble, A.J. Katz, B.A. Bunnell, Adipose-derived stem cells for regenerative
medicine, Circ. Res. 100 (2007) 1249–1260.
[64] C. Sengenès, K. Lolmède, A. Zakaroff-Girard, R. Busse, A. Bouloumié, Preadipocytes in
the human subcutaneous adipose tissue display distinct features from the adult mes-
enchymal and hematopoietic stem cells, J. Cell. Physiol. 205 (2005) 114–122.
[65] A. Monvoisin, J.A. Alva, J.J. Hofmann, A.C. Zovein, T.F. Lane, M.L. Iruela-Arispe,
VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination
in the endothelium, Dev. Dyn. 235 (2006) 3413–3422.
[66] J.K. Fraser, R. Schreiber, B. Strem,M. Zhu, Z. Alfonso, I.Wulur, M.H. Hedrick, Plasticity
of human adipose stem cells toward endothelial cells and cardiomyocytes, Nat. Clin.
Pract. Cardiovasc. Med. (2006).
[67] V. Planat-Benard, J.-S. Silvestre, B. Cousin, M. André, M. Nibbelink, R. Tamarat,
M. Clergue, C. Manneville, C. Saillan-Barreau, M. Duriez, A. Tedgui, B. Levy, L.
Pénicaud, L. Casteilla, Plasticity of human adipose lineage cells toward endo-
thelial cells, Circulation 109 (2004) 656–663.
[68] G.A. Ferraro, F. De Francesco, G. Nicoletti, F. Paino, V. Desiderio, V. Tirino, F. D'Andrea,
Human adipose CD34+CD90+ stem cells and collagen scaffold constructs grafted
in vivo fabricate loose connective and adipose tissues, J. Cell. Biochem. (2012),
n/a-n/a.
[69] S.M. Majka, K.E. Fox, J.C. Psilas, K.M. Helm, C.R. Childs, A.S. Acosta, R.C. Janssen, J.E.
Friedman, B.T.Woessner, T.R. Shade,M. Varella-Garcia, D.J. Klemm, De novo gener-
ation of white adipocytes from the myeloid lineage via mesenchymal intermedi-
ates is age, adipose depot, and gender speciﬁc, Proc. Natl. Acad. Sci. 107 (2010)
14781–14786.
366 Y.-H. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 358–369[70] J.T. Crossno, S.M. Majka, T. Grazia, R.G. Gill, D.J. Klemm, Rosiglitazone promotes
development of a novel adipocyte population from bone marrow-derived circu-
lating progenitor cells, J. Clin. Invest. 116 (2006) 3220–3228.
[71] Y. Sera, A.C. LaRue, O. Moussa, M. Mehrotra, J.D. Duncan, C.R. Williams, E. Nishimoto,
B.A. Schulte, P.M. Watson, D.K. Watson, M. Ogawa, Hematopoietic stem cell origin of
adipocytes, Experimental hematology, 37 (2009) 1108–1120.e1104.
[72] S.M. Majka, H.L. Miller, T. Sullivan, P.F. Erickson, R. Kong, M. Weiser-Evans, R.
Nemenoff, R. Moldovan, S.A. Morandi, J.A. Davis, D.J. Klemm, Adipose lineage spec-
iﬁcation of bone marrow-derived myeloid cells, Adipocyte 1 (2012) 215–229.
[73] Y.J. Koh, S. Kang, H.J. Lee, T.-S. Choi, H.S. Lee, C.-H. Cho, G.Y. Koh, Bonemarrow-derived
circulating progenitor cells fail to transdifferentiate into adipocytes in adult adipose
tissues in mice, J. Clin. Invest. 117 (2007) 3684–3695.
[74] R. Schoﬁeld, The relationship between the spleen colony-forming cell and the
haemopoietic stem cell, Blood Cells 4 (1978) 7–25.
[75] V. Greco, S. Guo, Compartmentalized organization: a common and required feature
of stem cell niches? Development 137 (2010) 1586–1594.
[76] K.A. Moore, I.R. Lemischka, Stem cells and their niches, Science 311 (2006)
1880–1885.
[77] L. Li, H. Clevers, Coexistence of quiescent and active adult stem cells in mammals,
Science 327 (2010) 542–545.
[78] K. Iyama, Electronmicroscopical studies on the genesis of white adipocytes: differ-
entiation of immature pericytes into adipocytes in transplanted preadipose tissue,
Virchows Archiv. B, Cell pathology 31 (1979) 143–155.
[79] S. Cinti, A morphological study of the adipocyte precursor, J. Submicrosc. Cytol.
16 (1984) 243–251.
[80] D.O. Traktuev, S. Merfeld-Clauss, J. Li, M. Kolonin, W. Arap, R. Pasqualini, B.H.
Johnstone, K.L. March, A population of multipotent CD34-positive adipose stromal
cells share pericyte and mesenchymal surface markers reside in a periendothelial
location, and stabilize endothelial networks, Circ. Res. 102 (2008) 77–85.
[81] H. Eto, H. Suga, D. Matsumoto, K. Inoue, N. Aoi, H. Kato, J. Araki, K. Yoshimura,
Characterization of structure and cellular components of aspirated and excised
adipose tissue, Plast. Reconstr. Surg. 124 (2009) 1087–1097, 1010.1097/
PRS.1080b1013e3181b1085a1083f1081.
[82] J.G. Granneman, P. Li, Y. Lu, J. Tilak, Seeing the trees in the forest: selective electro-
poration of adipocytes within adipose tissue, American Journal of Physiology—
Endocrinology And Metabolism 287 (2004) E574–E582.
[83] Subhra K. Biswas, A. Mantovani, Orchestration of metabolism by macrophages,
Cell Metab. 15 (2012) 432–437.
[84] O. Osborn, J.M. Olefsky, The cellular and signaling networks linking the immune
system and metabolism in disease, Nat. Med. 18 (2012) 363–374.
[85] S. Gordon, P.R. Taylor, Monocyte and macrophage heterogeneity, Nat. Rev. Immunol.
5 (2005) 953–964.
[86] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation,
Nat. Rev. Immunol. 8 (2008) 958–969.
[87] A. Sica, A. Mantovani, Macrophage plasticity and polarization: in vivo veritas.
(Science in medicine) (report), J. Clin. Invest. 122 (2012) 787(789).
[88] J.A. Levine, M.D. Jensen, N.L. Eberhardt, T. O'Brien, Adipocyte macrophage colony-
stimulating factor is a mediator of adipose tissue growth, J. Clin. Invest. 101 (1998)
1557–1564.
[89] J. Han, J.-E. Lee, J. Jin, J.S. Lim, N. Oh, K. Kim, S.-I. Chang,M. Shibuya, H. Kim, G.Y. Koh,
The spatiotemporal development of adipose tissue, Development 138 (2011)
5027–5037.
[90] W. Wiktor-Jedrzejczak, Correction by CSF-1 of defects in the osteopetrotic op/op
mouse suggests local, developmental, and humoral requirements for this growth
factor, Exp. Hematol. 19 (1991) 1049–1054.
[91] A.S. Molgat, A. Gagnon, A. Sorisky, Preadipocyte apoptosis is prevented by
macrophage-conditioned medium in a PDGF-dependent manner, Am. J. Physiol.
Cell Physiol. 296 (2009) C757–C765.
[92] C. Pang, Z. Gao, J. Yin, J. Zhang, W. Jia, J. Ye, Macrophage inﬁltration into adipose
tissue may promote angiogenesis for adipose tissue remodeling in obesity,
American Journal of Physiology—Endocrinology And Metabolism 295 (2008)
E313–E322.
[93] S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, A.W. Ferrante,
Obesity is associated with macrophage accumulation in adipose tissue, J. Clin.
Invest. 112 (2003) 1796–1808.
[94] C.N. Lumeng, J.L. Bodzin, A.R. Saltiel, Obesity induces a phenotypic switch in
adipose tissue macrophage polarization, J. Clin. Invest. 117 (2007) 175–184.
[95] J.I. Odegaard, A. Chawla, Alternative macrophage activation and metabolism,
Annual Review of Pathology: Mechanisms of Disease 6 (2011) 275–297.
[96] J.I. Odegaard, R.R. Ricardo-Gonzalez, M.H. Goforth, C.R. Morel, V. Subramanian, L.
Mukundan, A.R. Eagle, D. Vats, F. Brombacher, A.W. Ferrante, A. Chawla, Macro-
phage-speciﬁc PPAR[g] controls alternative activation and improves insulin resis-
tance, Nature 447 (2007) 1116–1120.
[97] K.D. Nguyen, Y. Qiu, X. Cui, Y.P.S. Goh, J. Mwangi, T. David, L. Mukundan, F.
Brombacher, R.M. Locksley, A. Chawla, Alternatively activated macrophages
produce catecholamines to sustain adaptive thermogenesis, Nature 480
(2011) 104–108.
[98] A. Kosteli, E. Sugaru, G. Haemmerle, J.F. Martin, J. Lei, R. Zechner, A.W. Ferrante,
Weight loss and lipolysis promote a dynamic immune response in murine adipose
tissue, J. Clin. Invest. 120 (2010) 3466–3479.
[99] Y. Cao, Angiogenesis modulates adipogenesis and obesity, J. Clin. Invest. 117
(2007) 2362–2368.
[100] S. Nishimura, I. Manabe, M. Nagasaki, Y. Hosoya, H. Yamashita, H. Fujita, M.
Ohsugi, K. Tobe, T. Kadowaki, R. Nagai, S. Sugiura, Adipogenesis in obesity re-
quires close interplay between differentiating adipocytes, Stromal Cells, and
Blood Vessels, Diabetes 56 (2007) 1517–1526.[101] M.A. Rupnick, D. Panigrahy, C.-Y. Zhang, S.M. Dallabrida, B.B. Lowell, R. Langer,
M.J. Folkman, Adipose tissue mass can be regulated through the vasculature,
Proc. Natl. Acad. Sci. 99 (2002) 10730–10735.
[102] K. Sun, I.W. Asterholm, C.M. Kusminski, A.C. Bueno, Z.V. Wang, J.W. Pollard, R.A.
Brekken, P.E. Scherer, Dichotomous effects of VEGF-A on adipose tissue dysfunc-
tion, Proc. Natl. Acad. Sci. 109 (2012) 5874–5879.
[103] L.J. Hutley, A.C. Herington, W. Shurety, C. Cheung, D.A. Vesey, D.P. Cameron, J.B.
Prins, Human adipose tissue endothelial cells promote preadipocyte proliferation,
American Journal of Physiology—Endocrinology And Metabolism 281 (2001)
E1037–E1044.
[104] F.E. Varzaneh, G. Shillabeer, K.L. Wong, D.C.W. Lau, Extracellular matrix components
secreted by microvascular endothelial cells stimulate preadipocyte differentiation in
vitro, Metabolism 43 (1994) 906–912.
[105] E. Bråkenhielm, R. Cao, B. Gao, B. Angelin, B. Cannon, P. Parini, Y. Cao, Angiogenesis
inhibitor, TNP-470 prevents diet-induced and genetic obesity in mice, Circ. Res. 94
(2004) 1579–1588.
[106] T.J. Bartness, C.K. Song, Thematic review series: adipocyte biology sympathetic and
sensory innervation of white adipose tissue, J. Lipid Res. 48 (2007) 1655–1672.
[107] M.T. Foster, T.J. Bartness, Sympathetic but not sensory denervation stimulates
white adipocyte proliferation, Am. J. Physiol. Regul. Integr. Comp. Physiol. 291
(2006) R1630–R1637.
[108] H. Shi, C.K. Song, A. Giordano, S. Cinti, T.J. Bartness, Sensory or sympathetic white
adipose tissue denervation differentially affects depot growth and cellularity, Am.
J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R1028–R1037.
[109] D.B.Hausman,M.DiGirolamo, T.J. Bartness, G.J. Hausman, R.J.Martin, The biology of
white adipocyte proliferation, Obes. Rev. 2 (2001) 239–254.
[110] B. Cousin, L. Casteilla, M. Lafontan, L. Ambid, D. Langin, M.F. Berthault, L. Pénicaud,
Local sympathetic denervation ofwhite adipose tissue in rats induces preadipocyte
proliferationwithout noticeable changes inmetabolism, Endocrinology 133 (1993)
2255–2262.
[111] D. Jones, T. Ramsay, G. Hausman, R. Martin, Norepinephrine inhibits rat pre-
adipocyte proliferation, Int. J. Obes. Relat. Metab. Disord. 16 (1992) 349–354.
[112] A. Bouloumié, V. Planat, J.C. Devedjian, P. Valet, J.S. Saulnier-Blache, M. Record,
M. Lafontan, Alpha 2-adrenergic stimulation promotes preadipocyte prolifera-
tion, Involvement of mitogen-activated protein kinases, Journal of Biological
Chemistry 269 (1994) 30254–30259.
[113] A. Geloen, A.J. Collet, L.J. Bukowiecki, Role of sympathetic innervation in brown
adipocyte proliferation, Am. J. Physiol. Regul. Integr. Comp. Physiol. 263 (1992)
R1176–R1181.
[114] G. Bronnikov, T. Bengtsson, L. Kramarova, V. Golozoubova, B. Cannon, J. Nedergaard,
{Beta}1 to {beta}3 switch in control of cyclic adenosine monophosphate during
brown adipocyte development explains distinct {beta}-adrenoceptor subtype me-
diation of proliferation and differentiation, Endocrinology 140 (1999) 4185–4197.
[115] T.J. Schulz, P. Huang, T.L. Huang, R. Xue, L.E. McDougall, K.L. Townsend, A.M.
Cypess, Y. Mishina, E. Gussoni, Y.-H. Tseng, Brown-fat paucity due to impaired
BMP signalling induces compensatory browning of white fat, Nature 495
(2013) 379–383.
[116] A.G. Cristancho, M.A. Lazar, Forming functional fat: a growing understanding of
adipocyte differentiation, Nat. Rev. Mol. Cell Biol. 12 (2011) 722–734.
[117] A. Divoux, K. Clément, Architecture and the extracellular matrix: the still
unappreciated components of the adipose tissue, Obes. Rev. 12 (2011) e494–e503.
[118] E.M. Mariman, P. Wang, Adipocyte extracellular matrix composition, dynamics
and role in obesity, Cell. Mol. Life Sci. 67 (2010) 1277–1292.
[119] I. Nakajima, S. Muroya, R.-i. Tanabe, K. Chikuni, Extracellular matrix development
during differentiation into adipocytes with a unique increase in type V and VI col-
lagen, Biol. Cell 94 (2002) 197–203.
[120] C. Pierleoni, F. Verdenelli, M. Castellucci, S. C., Fibronectins and basal lamina mole-
cules expression in human subcutaneous white adipose tissue, Eur. J. Histochem.
42 (1998) 183–188.
[121] B.M. Spiegelman, C.A. Ginty, Fibronectin modulation of cell shape and lipogenic
gene expression in 3T3-adipocytes, Cell 35 (1983) 657–666.
[122] V. Christiaens, I. Scroyen, H.R. Lijnen, Role of proteolysis in development of murine
adipose tissue, Thromb. Haemost. 99 (2008) 290–294.
[123] E. Maquoi, Enhanced nutritionally induced adipose tissue development in mice
with stromelysin-1 gene inactivation, Thromb. Haemost. 89 (2003) 696–704.
[124] H.R. Lijnen, Adipocyte hypertrophy in stromelysin-3 deﬁcient mice with nutri-
tionally induced obesity, Thromb. Haemost. 87 (2002) 530–535.
[125] C.M. Alexander, S. Selvarajan, J. Mudgett, Z. Werb, Stromelysin-1 regulates
adipogenesis during mammary gland involution, J. Cell Biol. 152 (2001)
693–703.
[126] G. Croissandeau, M. Chrétien, M. Mbikay, Involvement of matrix metalloproteinases
in the adipose conversion of 3T3-L1 preadipocytes, Biochem. J. 364 (2002) 739–746.
[127] A. Bouloumié, C. Sengenès, G. Portolan, J. Galitzky, M. Lafontan, Adipocyte produces
matrixmetalloproteinases 2 and9: involvement in adipose differentiation, Diabetes
50 (2001) 2080–2086.
[128] H.R. Lijnen, E. Maquoi, L.B. Hansen, B. Van Hoef, L. Frederix, D. Collen, Matrix
metalloproteinase inhibition impairs adipose tissue development in mice,
Arterioscler. Thromb. Vasc. Biol. 22 (2002) 374–379.
[129] T.-H. Chun, K.B. Hotary, F. Sabeh, A.R. Saltiel, E.D. Allen, S.J. Weiss, A pericellular
collagenase directs the 3-dimensional development of white adipose tissue, Cell
125 (2006) 577–591.
[130] T.A. Wynn, T.R. Ramalingam, Mechanisms of ﬁbrosis: therapeutic translation for
ﬁbrotic disease, Nat. Med. 18 (2012) 1028–1040.
[131] T. Khan, E.S. Muise, P. Iyengar, Z.V. Wang, M. Chandalia, N. Abate, B.B. Zhang, P.
Bonaldo, S. Chua, P.E. Scherer, Metabolic dysregulation and adipose tissue ﬁbrosis:
role of collagen VI, Mol. Cell. Biol. 29 (2009) 1575–1591.
367Y.-H. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 358–369[132] N. Halberg, T. Khan, M.E. Trujillo, I. Wernstedt-Asterholm, A.D. Attie, S. Sherwani,
Z.V. Wang, S. Landskroner-Eiger, S. Dineen, U.J. Magalang, R.A. Brekken, P.E.
Scherer, Hypoxia-inducible factor 1α induces ﬁbrosis and insulin resistance in
white adipose tissue, Mol. Cell. Biol. 29 (2009) 4467–4483.
[133] M. Spencer, A. Yao-Borengasser, R. Unal, N. Rasouli, C.M. Gurley, B. Zhu, C.A.
Peterson, P.A. Kern, Adipose tissue macrophages in insulin-resistant subjects
are associated with collagen VI and ﬁbrosis and demonstrate alternative activa-
tion, American Journal of Physiology—Endocrinology And Metabolism 299
(2010) E1016–E1027.
[134] V. Bourlier, C. Sengenès, A. Zakaroff-Girard, P. Decaunes, B.Wdziekonski, J. Galitzky,
P. Villageois, D. Esteve, P. Chiotasso, C. Dani, A. Bouloumié, TGFbeta familymembers
are key mediators in the induction of myoﬁbroblast phenotype of human adipose
tissue progenitor cells by macrophages, PLoS One 7 (2012) e31274.
[135] A. Uezumi, S.-i. Fukada, K. Tsuchida, Mesenchymal progenitors distinct from sat-
ellite cells contribute to ectopic fat cell formation in skeletal muscle, Nat. Cell
Biol. 12 (2010) 143–152.
[136] A. Uezumi, T. Ito, D. Morikawa, N. Shimizu, T. Yoneda, M. Segawa, M. Yamaguchi,
R. Ogawa, M.M. Matev, Y. Miyagoe-Suzuki, S.i. Takeda, K. Tsujikawa, K. Tsuchida,
H. Yamamoto, S.-i. Fukada, Fibrosis and adipogenesis originate from a common
mesenchymal progenitor in skeletal muscle, J. Cell Sci. 124 (2011) 3654–3664.
[137] A.W.B. Joe, L. Yi, A. Natarajan, F. Le Grand, L. So, J. Wang, M.A. Rudnicki, F.M.V.
Rossi, Muscle injury activates resident ﬁbro/adipogenic progenitors that facili-
tate myogenesis, Nat. Cell Biol. 12 (2010) 153–163.
[138] S. Dulauroy, S.E. Di Carlo, F. Langa, G. Eberl, L. Peduto, Lineage tracing and genet-
ic ablation of ADAM12+ perivascular cells identify a major source of proﬁbrotic
cells during acute tissue injury, Nat. Med. 18 (2012) 1262–1270.
[139] C.H. Hollenberg, A. Vost, Regulation of DNA synthesis in fat cells and stromal
elements from rat adipose tissue, J. Clin. Invest. 47 (1969) 2485–2498.
[140] J.L. Knittle, K. Timmers, F. Ginsberg-Fellner, R.E. Brown, D.P. Katz, The growth of
adipose tissue in children and adolescents. Cross-sectional and longitudinal
studies of adipose cell number and size, J. Clin. Invest. 63 (1979) 239–246.
[141] K.L. Spalding, E. Arner, P.O. Westermark, S. Bernard, B.A. Buchholz, O. Bergmann, L.
Blomqvist, J. Hoffstedt, E. Naslund, T. Britton, H. Concha, M. Hassan, M. Ryden, J.
Frisen, P. Arner, Dynamics of fat cell turnover inhumans,Nature 453 (2008) 783–787.
[142] J.L. Knittle, J. Hirsch, Effect of early nutrition on the development of rat epididymal
fat pads: cellularity and metabolism, J. Clin. Invest. 47 (1968) 2091–2098.
[143] A. Strawford, F. Antelo, M. Christiansen, M.K. Hellerstein, Adipose tissue triglyceride
turnover, de novo lipogenesis, and cell proliferation in humans measured with
2H2O, American Journal of Physiology—Endocrinology And Metabolism 286 (2004)
E577–E588.
[144] A. Rigamonti, K. Brennand, F. Lau, C.A. Cowan, Rapid cellular turnover in adipose
tissue, PLoS One 6 (2011) e17637.
[145] A.W.B. Joe, L. Yi, Y. Even, A.W. Vogl, F.M.V. Rossi, Depot-speciﬁc differences in
adipogenic progenitor abundance and proliferative response to high-fat diet,
Stem Cells 27 (2009) 2563–2570.
[146] Y. Tchoukalova, S. Votruba, T. Tchkonia, N. Giorgadze, J. Kirkland,M. Jensen, Regional
differences in cellular mechanisms of adipose tissue gain with overfeeding, Proc.
Natl. Acad. Sci. U.S.A. 107 (2010) 18226–18231.
[147] J. Hirsch, B. Batchelor, Adipose tissue cellularity in human obesity, Clin. Endocrinol.
Metab. 5 (1976) 299–311.
[148] M. Maumus, C. Sengenès, P. Decaunes, A. Zakaroff-Girard, V. Bourlier, M. Lafontan, J.
Galitzky, A. Bouloumié, Evidence of in situ proliferation of adult adipose tissue-
derived progenitor cells: inﬂuence of fat mass microenvironment and growth,
J. Clin. Endocrinol. Metab. 93 (2008) 4098–4106.
[149] O.T. Hardy, M.P. Czech, S. Corvera, What causes the insulin resistance underlying
obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19 (2012) 81–87.
[150] J.G. Granneman, P. Li, Z. Zhu, Y. Lu,Metabolic and cellular plasticity inwhite adipose
tissue I: effects of beta3-adrenergic receptor activation, Am. J. Physiol. Endocrinol.
Metab. 289 (2005) E608–E616.
[151] J. Himms-Hagen, J. Cui, E. Danforth Jr., D.J. Taatjes, S.S. Lang, B.L. Waters, T.H. Claus,
Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown
and white adipose tissues in rats, Am. J. Physiol. 266 (1994) R1371–R1382.
[152] B. Cousin, S. Cinti, M. Morroni, S. Raimbault, D. Ricquier, L. Penicaud, L. Casteilla,
Occurrence of brown adipocytes in rat white adipose tissue: molecular andmor-
phological characterization, J. Cell Sci. 103 (1992) 931–942.
[153] M. Ghorbani, J. Himms-Hagen, Appearance of brown adipocytes in white adipose
tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa
rats, Int. J. Obes. Relat. Metab. Disord. 21 (1997) 465–475.
[154] D. Grujic, V.S. Susulic, M.E. Harper, J. Himms-Hagen, B.A. Cunningham, B.E.
Corkey, B.B. Lowell, Beta3-adrenergic receptors on white and brown adipocytes
mediate beta3-selective agonist-induced effects on energy expenditure, insulin
secretion, and food intake, A study using transgenic and gene knockout mice, J
Biol Chem 272 (1997) 17686–17693.
[155] B. Xue, J.-S. Rim, J. Hogan, A. Coulter, R. Koza, L. Kozak, Genetic variability affects
the development of brown adipocytes in white fat but not in interscapular
brown fat, J. Lipid Res. 48 (2007) 41–51.
[156] L.P. Kozak, The genetics of brown adipocyte induction in white fat depots, Front
Endocrinol (Lausanne) 2 (2011) 64.
[157] D. Loncar, B.A. Afzelius, B. Cannon, Epididymal white adipose tissue after cold
stress in rats. II. Mitochondrial changes, J. Ultrastruct. Mol. Struct. Res. 101
(1988) 199–209.
[158] D. Loncar, B.A. Afzelius, B. Cannon, Epididymalwhite adipose tissue after cold stress
in rats. I. Nonmitochondrial changes, J. Ultrastruct. Mol. Struct. Res. 101 (1988)
109–122.
[159] D. Loncar, Convertible adipose tissue in mice, Cell Tissue Res. 266 (1991)
149–161.[160] N. Petrovic, T.B. Walden, I.G. Shabalina, J.A. Timmons, B. Cannon, J.
Nedergaard, Chronic peroxisome proliferator-activated receptor γ (PPARγ)
activation of epididymally derived white adipocyte cultures reveals a popu-
lation of thermogenically competent, UCP1-containing adipocytes molecu-
larly distinct from classic brown adipocytes, J. Biol. Chem. 285 (2010)
7153–7164.
[161] D. Loncar, B.A. Afzelius, Ontogenetical changes in adipose tissue of the cat: con-
vertible adipose tissue, J. Ultrastruct. Mol. Struct. Res. 102 (1989) 9–23.
[162] T.J. Schulz, T.L. Huang, T.T. Tran, H. Zhang, K.L. Townsend, J.L. Shadrach, M.
Cerletti, L.E. McDougall, N. Giorgadze, T. Tchkonia, D. Schrier, D. Falb, J.L.
Kirkland, A.J. Wagers, Y.-H. Tseng, Identiﬁcation of inducible brown adipocyte
progenitors residing in skeletal muscle and white fat, Proc. Natl. Acad. Sci. USA
108 (2011) 143–148.
[163] J. Himms-Hagen, A. Melnyk, M.C. Zingaretti, E. Ceresi, G. Barbatelli, S. Cinti,
Multilocular fat cells in WAT of CL-316243-treated rats derive directly from
white adipocytes, Am. J. Physiol. Cell Physiol. 279 (2000) C670–C681.
[164] V. Gouon-Evans, J. Pollard, Unexpected deposition of brown fat inmammary gland
during postnatal development, Molecular endocrinology (Baltimore, Md.) 16
(2002) 2618–2627.
[165] D. Loncar, Development of thermogenic adipose tissue, Int. J. Dev. Biol. 35 (1991)
321–333.
[166] P. Li, Z. Zhu, Y. Lu, J.G. Granneman,Metabolic and cellular plasticity inwhite adipose
tissue II: role of peroxisome proliferator-activated receptor-α, Am. J. Physiol.
Endocrinol. Metab. 289 (2005) E617–E626.
[167] E.P. Mottillo, X.J. Shen, J.G. Granneman, beta3-adrenergic receptor induction of
adipocyte inﬂammation requires lipolytic activation of stress kinases p38 and
JNK, Biochim. Biophys. Acta 1801 (2010) 1048–1055.
[168] E.P. Mottillo, X.J. Shen, J.G. Granneman, Role of hormone-sensitive lipase in
beta-adrenergic remodeling of white adipose tissue, Am. J. Physiol. Endocrinol.
Metab. 293 (2007) E1188–E1197.
[169] J.G. Granneman, M. Burnazi, Z. Zhu, L.A. Schwamb, White adipose tissue contributes
to UCP1-independent thermogenesis, Am. J. Physiol. Endocrinol. Metab. 285 (2003)
E1230–E1236.
[170] J. Ukropec, R.P. Anunciado, Y. Ravussin, M.W. Hulver, L.P. Kozak,
UCP1-independent thermogenesis in white adipose tissue of cold-acclimated
Ucp1-/- mice, J. Biol. Chem. 281 (2006) 31894–31908.
[171] S.P. Weisberg, D. Hunter, R. Huber, J. Lemieux, S. Slaymaker, K. Vaddi, I. Charo, R.L.
Leibel, A.W. Ferrante Jr., CCR2 modulates inﬂammatory and metabolic effects of
high-fat feeding, J. Clin. Invest. 116 (2006) 115–124.
[172] A.R. Johnson, J.J. Milner, L. Makowski, The inﬂammation highway: metabolism
accelerates inﬂammatory trafﬁc in obesity, Immunol. Rev. 249 (2012)
218–238.
[173] C.N. Lumeng, A.R. Saltiel, Inﬂammatory links between obesity and metabolic dis-
ease, J. Clin. Invest. 121 (2011) 2111–2117.
[174] S. Cinti, G. Mitchell, G. Barbatelli, I. Murano, E. Ceresi, E. Faloia, S. Wang, M.
Fortier, A.S. Greenberg, M.S. Obin, Adipocyte death deﬁnes macrophage localiza-
tion and function in adipose tissue of obese mice and humans, J. Lipid Res. 46
(2005) 2347–2355.
[175] A.B. Goldﬁne, V. Fonseca, S.E. Shoelson, Therapeutic approaches to target inﬂam-
mation in type 2 diabetes, Clin. Chem. 57 (2011) 162–167.
[176] M. Gregor, G. Hotamisligil, Inﬂammatory mechanisms in obesity, Annu. Rev.
Immunol. 29 (2011) 415–445.
[177] K. Sun, C.M. Kusminski, P.E. Scherer, Adipose tissue remodeling and obesity, J. Clin.
Invest. 121 (2011) 2094–2101.
[178] A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking
obesity to insulin resistance and type 2 diabetes, Nat. Rev. Mol. Cell Biol. 9 (2008)
367–377.
[179] J.M.Wentworth, G. Naselli,W.A. Brown, L. Doyle, B. Phipson,G.K. Smyth,M.Wabitsch,
P.E. O'Brien, L.C. Harrison, Pro-inﬂammatory CD11c+CD206+adipose tissuemacro-
phages are associated with insulin resistance in human obesity, Diabetes 59 (2010)
1648–1656.
[180] C. Glass, J. Olefsky, Inﬂammation and lipid signaling in the etiology of insulin resis-
tance, Cell Metab. 15 (2012) 635–645.
[181] Y. Tchoukalova, C. Koutsari, M. Jensen, Committed subcutaneous preadipocytes
are reduced in human obesity, Diabetologia 50 (2007) 151–157.
[182] M. Roldan, M. Macias-Gonzalez, R. Garcia, F.J. Tinahones, M. Martin, Obesity
short-circuits stemness gene network in human adipose multipotent stem cells,
FASEB J. 25 (2011) 4111–4126.
[183] P. Isakson, A. Hammarstedt, B. Gustafson, U. Smith, Impairedpreadipocyte differen-
tiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and
inﬂammation, Diabetes 58 (2009) 1550–1557.
[184] I. Karagiannides, T. Tchkonia, D.E. Dobson, C.M. Steppan, P. Cummins, G. Chan, K.
Salvatori, M. Hadzopoulou-Cladaras, J.L. Kirkland, Altered expression of C/EBP
family members results in decreased adipogenesis with aging, Am. J. Physiol.
Regul. Integr. Comp. Physiol. 280 (2001) R1772–R1780.
[185] G. Caso, M.A.McNurlan, I. Mileva, A. Zemlyak, D.C.Mynarcik, M.C. Gelato, Peripher-
al fat loss and decline in adipogenesis in older humans, Metabolism (2012).
[186] T. Tchkonia, D.Morbeck, T. Von Zglinicki, J. Van Deursen, J. Lustgarten, H. Scrable, S.
Khosla, M. Jensen, J. Kirkland, Fat tissue, aging, and cellular senescence, Aging Cell 9
(2010) 667–684.
[187] T. Minamino, M. Orimo, I. Shimizu, T. Kunieda, M. Yokoyama, T. Ito, A. Nojima, A.
Nabetani, Y. Oike, H. Matsubara, F. Ishikawa, I. Komuro, A crucial role for adipose
tissue p53 in the regulation of insulin resistance, Nat. Med. 15 (2009) 1082–1087.
[188] D. Baker, T. Wijshake, T. Tchkonia, N. LeBrasseur, B. Childs, B. van de Sluis, J.
Kirkland, J. van Deursen, Clearance of p16Ink4a-positive senescent cells delays
ageing-associated disorders, Nature 479 (2011) 232–236.
368 Y.-H. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 358–369[189] N. Rogers, A. Landa, S. Park, R. Smith, Aging leads to a programmed loss of brown
adipocytes in murine subcutaneous white adipose tissue, Aging Cell 11 (2012)
1074–1083.
[190] J. Arch, The discovery of drugs for obesity, the metabolic effects of leptin and
variable receptor pharmacology: perspectives from β3-adrenoceptor agonists,
Naunyn Schmiedebergs Arch. Pharmacol. 378 (2008) 225–240.
[191] A. Chawla, E.J. Schwarz, D.D. Dimaculangan, M.A. Lazar, Peroxisome proliferator-
activated receptor (PPAR) gamma: adipose-predominant expression and induction
early in adipocyte differentiation, Endocrinology 135 (1994) 798–800.
[192] P. Tontonoz, E. Hu, B.M. Spiegelman, Stimulation of adipogenesis in ﬁbroblasts by
PPAR gamma 2, a lipid-activated transcription factor, Cell 79 (1994) 1147–1156.
[193] B.M. Spiegelman, PPAR-gamma: adipogenic regulator and thiazolidinedione receptor,
Diabetes 47 (1998) 507–514.
[194] J. Seufert, G. Lubben, K. Dietrich, P.C. Bates, A comparison of the effects of
thiazolidinediones and metformin on metabolic control in patients with type 2
diabetes mellitus, Clin. Ther. 26 (2004) 805–818.
[195] D. Cipolletta, M. Feuerer, A. Li, N. Kamei, J. Lee, S. Shoelson, C. Benoist, D. Mathis,
PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue
Treg cells, Nature 486 (2012) 549–553.
[196] K.K. Ryan, B. Li, B.E. Grayson, E.K. Matter, S.C. Woods, R.J. Seeley, A role for central
nervous system PPAR-gamma in the regulation of energy balance, Nat. Med. 17
(2011) 623–626.
[197] A.L. Hevener, W. He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R.M.
Evans, J. Olefsky, Muscle-speciﬁc Pparg deletion causes insulin resistance, Nat.
Med. 9 (2003) 1491–1497.
[198] W. He, Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J.M. Olefsky,
R.M. Evans, Adipose-speciﬁc peroxisomeproliferator-activated receptor Î3 knockout
causes insulin resistance in fat and liver but not inmuscle, Proc. Natl. Acad. Sci. U.S.A.
100 (2003) 15712–15717.
[199] S. Sugii, P. Olson, D.D. Sears,M. Saberi, A.R. Atkins, G.D. Barish, S.H. Hong, G.L. Castro,
Y.Q. Yin, M.C. Nelson, G. Hsiao, D.R. Greaves, M. Downes, R.T. Yu, J.M. Olefsky, R.M.
Evans, PPARgamma activation in adipocytes is sufﬁcient for systemic insulin sensi-
tization, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 22504–22509.
[200] M. Laplante,W.T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, Y. Deshaies, Involvement of
adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat,
Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R1408–R1417.
[201] S.R. Smith, L. De Jonge, J. Volaufova, Y. Li, H. Xie, G.A. Bray, Effect of pioglitazone
on body composition and energy expenditure: a randomized controlled trial,
Metabolism 54 (2005) 24–32.
[202] S. Shadid, C.D. Stehouwer, M.D. Jensen, Diet/Exercise versus pioglitazone: effects
of insulin sensitization with decreasing or increasing fat mass on adipokines and
inﬂammatory markers, J. Clin. Endocrinol. Metab. 91 (2006) 3418–3425.
[203] J. Fruebis, T.-S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R.S. Erickson, F.T. Yen, B.E. Bihain,
H.F. Lodish, Proteolytic cleavage product of 30-kDa adipocyte complement-related
protein increases fatty acid oxidation in muscle and causes weight loss in mice,
Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2005–2010.
[204] J. Tonelli, W. Li, P. Kishore, U.B. Pajvani, E. Kwon, C. Weaver, P.E. Scherer, M.
Hawkins, Mechanisms of early insulin-sensitizing effects of thiazolidinediones
in type 2 diabetes, Diabetes 53 (2004) 1621–1629.
[205] A.R. Nawrocki, M.W. Rajala, E. Tomas, U.B. Pajvani, A.K. Saha, M.E. Trumbauer, Z.
Pang, A.S. Chen, N.B. Ruderman, H. Chen, L. Rossetti, P.E. Scherer, Mice lacking
adiponectin show decreased hepatic insulin sensitivity and reduced responsive-
ness to peroxisome proliferator-activated receptor gamma agonists, J. Biol.
Chem. 281 (2006) 2654–2660.
[206] P.D. Miles, O.M. Romeo, K. Higo, A. Cohen, K. Rafaat, J.M. Olefsky, TNF-alpha-induced
insulin resistance in vivo and its prevention by troglitazone, Diabetes 46 (1997)
1678–1683.
[207] G. Chinetti, J.C. Fruchart, B. Staels, Peroxisome proliferator-activated receptors
(PPARs): nuclear receptors at the crossroads between lipid metabolism and inﬂam-
mation, Inﬂamm. Res. 49 (2000) 497–505.
[208] R. Stienstra, C. Duval, S. Keshtkar, J. van der Laak, S. Kersten, M. Muller, Peroxisome
proliferator-activated receptor gammaactivation promotes inﬁltration of alternative-
ly activatedmacrophages into adipose tissue, J. Biol. Chem. 283 (2008) 22620–22627.
[209] J. Jonker, J. Suh, A. Atkins, M. Ahmadian, P. Li, J. Whyte, M. He, H. Juguilon, Y.-Q.
Yin, C. Phillips, R. Yu, J. Olefsky, R. Henry, M. Downes, R. Evans, A PPARγ-FGF1
axis is required for adaptive adipose remodelling and metabolic homeostasis,
Nature 485 (2012) 391–394.
[210] P. Dutchak, T. Katafuchi, A. Bookout, J. Choi, R. Yu, D. Mangelsdorf, S. Kliewer, Fibro-
blast growth factor-21 regulates PPARγ activity and the antidiabetic actions of
thiazolidinediones, Cell 148 (2012) 556–567.
[211] H.P. Guan, Y. Li, M.V. Jensen, C.B. Newgard, C.M. Steppan, M.A. Lazar, A futile meta-
bolic cycle activated in adipocytes by antidiabetic agents, Nat. Med. 8 (2002)
1122–1128.
[212] L. Wilson-Fritch, S. Nicoloro, M. Chouinard, M.A. Lazar, P.C. Chui, J. Leszyk, J.
Straubhaar, M.P. Czech, S. Corvera, Mitochondrial remodeling in adipose tissue
associated with obesity and treatment with rosiglitazone, J. Clin. Invest. 114
(2004) 1281–1289.
[213] D.D. Sears, G. Hsiao, A. Hsiao, J.G. Yu, C.H. Courtney, J.M. Ofrecio, J. Chapman, S.
Subramaniam, Mechanisms of human insulin resistance and thiazolidinedione-
mediated insulin sensitization, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 18745–18750.
[214] H. Ohno, K. Shinoda, B.M. Spiegelman, S. Kajimura, PPARgamma agonists induce
a white-to-brown fat conversion through stabilization of PRDM16 protein, Cell
Metab. 15 (2012) 395–404.
[215] C. Vernochet, S.B. Peres, K.E. Davis, M.E. McDonald, L. Qiang, H. Wang, P.E.
Scherer, S.R. Farmer, C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate
repression of select visceral white adipose genes during induction of the brownphenotype in white adipocytes by peroxisome proliferator-activated receptor
gamma agonists, Mol. Cell. Biol. 29 (2009) 4714–4728.
[216] L. Qiang, L. Wang, N. Kon, W. Zhao, S. Lee, Y. Zhang, M. Rosenbaum, Y. Zhao, W.
Gu, S.R. Farmer, D. Accili, Brown remodeling of white adipose tissue by
SirT1-dependent deacetylation of Ppargamma, Cell 150 (2012) 620–632.
[217] M.S. Siersbaek, A. Loft, M.M. Aagaard, R. Nielsen, S.F. Schmidt, N. Petrovic, J.
Nedergaard, S. Mandrup, Genome-wide proﬁling of peroxisome proliferator-
activated receptor gamma in primary epididymal, inguinal, and brown adipo-
cytes reveals depot-selective binding correlated with gene expression, Mol.
Cell. Biol. 32 (2012) 3452–3463.
[218] C. Elabd, C. Chiellini, M. Carmona, J. Galitzky, O. Cochet, R. Petersen, L. Penicaud,
K. Kristiansen, A. Bouloumie, L. Casteilla, C. Dani, G. Ailhaud, E.Z. Amri, Human
multipotent adipose-derived stem cells differentiate into functional brown adi-
pocytes, Stem Cells 27 (2009) 2753–2760.
[219] T. Yoshida, N. Sakane, Y. Wakabayashi, T. Umekawa, M. Kondo, Anti-obesity and
anti-diabetic effects of CL 316,243, a highly speciﬁc beta 3-adrenoceptor agonist,
in yellow KK mice, Life Sci. 54 (1994) 491–498.
[220] P. Li, Z. Zhu, Y. Lu, J.G. Granneman,Metabolic and cellular plasticity inwhite adipose
tissue II: role of peroxisome proliferator-activated receptor-alpha, Am. J. Physiol.
Endocrinol. Metab. 289 (2005) E617–E626.
[221] M.A. Cawthorne, M.V. Sennitt, J.R. Arch, S.A. Smith, BRL 35135, a potent and selec-
tive atypical beta-adrenoceptor agonist, Am. J. Clin. Nutr. 55 (1992) 252S–257S.
[222] S. Collins, E. Yehuda-Shnaidman, H. Wang, Positive and negative control of Ucp1
gene transcription and the role of beta-adrenergic signaling networks, Int. J.
Obes. (Lond) 34 (Suppl. 1) (2010) S28–S33.
[223] W. Cao, K.W. Daniel, J. Robidoux, P. Puigserver, A.V. Medvedev, X. Bai, L.M.
Floering, B.M. Spiegelman, S. Collins, p38 mitogen-activated protein kinase is
the central regulator of cyclic AMP-dependent transcription of the brown fat
uncoupling protein 1 gene, Mol. Cell. Biol. 24 (2004) 3057–3067.
[224] J.S. Rim, L.P. Kozak, Regulatory motifs for CREB-binding protein and Nfe2l2 tran-
scription factors in the upstreamenhancer of themitochondrial uncouplingprotein
1 gene, J. Biol. Chem. 277 (2002) 34589–34600.
[225] M. Uldry, W. Yang, J. St-Pierre, J. Lin, P. Seale, B.M. Spiegelman, Complementary
action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat dif-
ferentiation, Cell Metab. 3 (2006) 333–341.
[226] P. Puigserver, Z. Wu, C.W. Park, R. Graves, M. Wright, B.M. Spiegelman, A cold-
inducible coactivator of nuclear receptors linked to adaptive thermogenesis, Cell
92 (1998) 829–839.
[227] J.S. Chang, V. Fernand, Y. Zhang, J. Shin, H.J. Jun, Y. Joshi, T.W. Gettys, NT-PGC-1alpha
protein is sufﬁcient to link beta3-adrenergic receptor activation to transcriptional
and physiological components of adaptive thermogenesis, J. Biol. Chem. 287
(2012) 9100–9111.
[228] B. Xue, A. Coulter, J.S. Rim, R.A. Koza, L.P. Kozak, Transcriptional synergy and the
regulation of Ucp1 during brown adipocyte induction in white fat depots, Mol.
Cell. Biol. 25 (2005) 8311–8322.
[229] E.P. Mottillo, A.E. Bloch, T. Leff, J.G. Granneman, Lipolytic products activate per-
oxisome proliferator-activated receptor (PPAR) α and δ in brown adipocytes to
match fatty acid oxidation with supply, J. Biol. Chem. 287 (2012) 25038–25048.
[230] R.J. Roth Flach, A. Matevossian, T.E. Akie, K.A. Negrin, M.T. Paul, M.P. Czech,
Beta3-Adrenergic receptor stimulation induces E-selectin-mediated adipose tis-
sue inﬂammation, J. Biol. Chem. 288 (2013) 2882–2892.
[231] M. Ahmadian, Marcia J. Abbott, T. Tang, Carolyn S.S. Hudak, Y. Kim, M. Bruss,
Marc K. Hellerstein, H.-Y. Lee, Varman T. Samuel, Gerald I. Shulman, Y. Wang,
Robin E. Duncan, C. Kang, Hei S. Sul, Desnutrin/ATGL is regulated by AMPK
and is required for a brown adipose phenotype, Cell Metab. 13 (2011) 739–748.
[232] P. Bostrom, J. Wu, M.P. Jedrychowski, A. Korde, L. Ye, J.C. Lo, K.A. Rasbach, E.A.
Bostrom, J.H. Choi, J.Z. Long, S. Kajimura, M.C. Zingaretti, B.F. Vind, H. Tu, S.
Cinti, K. Hojlund, S.P. Gygi, B.M. Spiegelman, A PGC1-alpha-dependent myokine
that drives brown-fat-like development of white fat and thermogenesis, Nature
481 (2012) 463–468.
[233] J.A. Timmons, K. Baar, P.K. Davidsen, P.J. Atherton, Is irisin a human exercise
gene? Nature 488 (2012) E9–E10.
[234] J.Y. Huh, G. Panagiotou, V. Mougios, M. Brinkoetter, M.T. Vamvini, B.E. Schneider,
C.S. Mantzoros, FNDC5 and irisin in humans: I. Predictors of circulating concentra-
tions in serum and plasma and II. mRNA expression and circulating concentrations
in response to weight loss and exercise, Metabolism 61 (2012) 1725–1738.
[235] K.L. Townsend, D. An, M.D. Lynes, T.L. Huang, H. Zhang, L.J. Goodyear, Y.H. Tseng, In-
creased mitochondrial activity in BMP7-treated brown adipocytes, due to increased
CPT1- and CD36-mediated fatty acid uptake, Antioxid. Redox Signal. (2012).
[236] A. Whittle, S. Carobbio, L. Martins, M. Slawik, E. Hondares, M. Vázquez, D. Morgan,
R. Csikasz, R. Gallego, S. Rodriguez-Cuenca, M. Dale, S. Virtue, F. Villarroya, B.
Cannon, K. Rahmouni, M. López, A. Vidal-Puig, BMP8B increases brown adipose tis-
sue thermogenesis through both central and peripheral actions, Cell 149 (2012)
871–885.
[237] E. Hondares, M. Rosell, F. Gonzalez, M. Giralt, R. Iglesias, F. Villarroya, Hepatic
FGF21 expression is induced at birth via PPARalpha in response to milk intake
and contributes to thermogenic activation of neonatal brown fat, Cell Metab.
11 (2010) 206–212.
[238] F. Fisher, S. Kleiner, N. Douris, E. Fox, R. Mepani, F. Verdeguer, J. Wu, A.
Kharitonenkov, J. Flier, E. Maratos-Flier, B. Spiegelman, FGF21 regulates PGC-
1α and browning of white adipose tissues in adaptive thermogenesis, Genes
Dev. 26 (2012) 271–281.
[239] D. Chartoumpekis, I. Habeos, P. Ziros, A. Psyrogiannis, V. Kyriazopoulou, A.
Papavassiliou, Brown adipose tissue responds to cold and adrenergic stimula-
tion by induction of FGF21, Molecular medicine (Cambridge, Mass.) 17 (2011)
736–740.
369Y.-H. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 358–369[240] A.C. Adams, C.C. Cheng, T. Coskun, A. Kharitonenkov, FGF21 requires betaklotho
to act in vivo, PLoS One 7 (2012) e49977.
[241] X. Ding, J. Boney-Montoya, B.M. Owen, A.L. Bookout, K.C. Coate, D.J. Mangelsdorf,
S.A. Kliewer, BetaKlotho is required for ﬁbroblast growth factor 21 effects on
growth and metabolism, Cell Metab. 16 (2012) 387–393.
[242] I.N. Foltz, S. Hu, C. King, X.Wu, C. Yang,W.Wang, J.Weiszmann, J. Stevens, J.S. Chen,
N. Nuanmanee, J. Gupte, R. Komorowski, L. Sekirov, T. Hager, T. Arora, H. Ge, H.
Baribault, F. Wang, J. Sheng, M. Karow, M. Wang, Y. Luo, W. McKeehan, Z. Wang,
M.M. Veniant, Y. Li, Treating diabetes and obesity with an FGF21-mimetic antibody
activating the betaKlotho/FGFR1c receptor complex, Sci. Transl. Med. 4 (2012)
162ra153.
[243] P. Lee, R.J. Brychta, J. Linderman, S. Smith, K.Y. Chen, F.S. Celi, Mild cold exposure
modulates ﬁbroblast growth factor 21 (FGF21) diurnal rhythm in humans: rela-
tionship between FGF21 levels, lipolysis, and cold-induced thermogenesis, J. Clin.
Endocrinol. Metab. (2012).
[244] S.Ma, H. Yu, Z. Zhao, Z. Luo, J. Chen, Y. Ni, R. Jin, L. Ma, P.Wang, Z. Zhu, L. Li, J. Zhong,
D. Liu, B. Nilius, Z. Zhu, Activation of the cold-sensing TRPM8 channel triggers
UCP1-dependent thermogenesis and prevents obesity, J. Mol. Cell Biol. 4 (2012)
88–96.
[245] P. Seale, H.M. Conroe, J. Estall, S. Kajimura, A. Frontini, J. Ishibashi, P. Cohen, S.
Cinti, B.M. Spiegelman, Prdm16 determines the thermogenic program of subcu-
taneous white adipose tissue in mice, J. Clin. Invest. 121 (2011) 96–105.
[246] M. Christian, E. Kiskinis, D. Debevec, G. Leonardsson, R. White, M. Parker,
RIP140-targeted repression of gene expression in adipocytes, Mol. Cell. Biol. 25
(2005) 9383–9391.
[247] A. Scime, G. Grenier, M.S. Huh, M.A. Gillespie, L. Bevilacqua, M.E. Harper, M.A.
Rudnicki, Rb and p107 regulate preadipocyte differentiation into white versus
brown fat through repression of PGC-1alpha, Cell Metab. 2 (2005) 283–295.
[248] A. Cederberg, L.M. Gronning, B. Ahren, K. Tasken, P. Carlsson, S. Enerback, FOXC2
is a winged helix gene that counteracts obesity, hypertriglyceridemia, and
diet-induced insulin resistance, Cell 106 (2001) 563–573.
[249] M. Lafontan, C.Moro,M. Berlan, F. Crampes, C. Sengenes, J. Galitzky, Control of lipol-
ysis by natriuretic peptides and cyclic GMP, Trends Endocrinol. Metab. 19 (2008)
130–137.
[250] M. Bordicchia, D. Liu, E.Z. Amri, G. Ailhaud, P. Dessi-Fulgheri, C. Zhang, N.
Takahashi, R. Sarzani, S. Collins, Cardiac natriuretic peptides act via p38 MAPK
to induce the brown fat thermogenic program in mouse and human adipocytes,
J. Clin. Invest. 122 (2012) 1022–1036.
[251] A.L. Birkenfeld, P. Budziarek, M. Boschmann, C. Moro, F. Adams, G. Franke, M.
Berlan, M.A. Marques, F.C. Sweep, F.C. Luft, M. Lafontan, J. Jordan, Atrial natri-
uretic peptide induces postprandial lipid oxidation in humans, Diabetes 57
(2008) 3199–3204.
[252] S. Engeli, A.L. Birkenfeld, P.M. Badin, V. Bourlier, K. Louche, N. Viguerie, C. Thalamas,
E. Montastier, D. Larrouy, I. Harant, I. de Glisezinski, S. Lieske, J. Reinke, B.
Beckmann, D. Langin, J. Jordan, C.Moro, Natriuretic peptides enhance the oxidative
capacity of human skeletal muscle, J. Clin. Invest. 122 (2012) 4675–4679.
[253] J.R. Arch, A.T. Ainsworth, M.A. Cawthorne, V. Piercy, M.V. Sennitt, V.E. Thody, C.
Wilson, S. Wilson, Atypical beta-adrenoceptor on brown adipocytes as target for
anti-obesity drugs, Nature 309 (1984) 163–165.[254] A. Cypess, Y.-C. Chen, C. Sze, K. Wang, J. English, O. Chan, A. Holman, I. Tal, M.
Palmer, G. Kolodny, C. Kahn, Cold but not sympathomimetics activates
human brown adipose tissue in vivo, Proc. Natl. Acad. Sci. U.S.A. 109 (2012)
10001–10005.
[255] A. Carey, M. Formosa, B. Van Every, D. Bertovic, N. Eikelis, G. Lambert, V. Kalff, S.
Duffy, M. Cherk, B. Kingwell, Ephedrine activates brown adipose tissue in lean
but not obese humans, Diabetologia (2012).
[256] M.J. Vosselman, A.A. van der Lans, B. Brans, R. Wierts, M.A. van Baak, P. Schrauwen,
W.D. vanMarken Lichtenbelt, Systemic beta-adrenergic stimulation of thermogen-
esis is not accompanied by brown adipose tissue activity in humans, Diabetes 61
(2012) 3106–3113.
[257] D.G. Nicholls, E. Rial, A history of the ﬁrst uncoupling protein, UCP1, J. Bioenerg.
Biomembr. 31 (1999) 399–406.
[258] G. Haemmerle, T. Moustafa, G. Woelkart, S. Buttner, A. Schmidt, T. van deWeijer,
M. Hesselink, D. Jaeger, P.C. Kienesberger, K. Zierler, R. Schreiber, T. Eichmann, D.
Kolb, P. Kotzbeck, M. Schweiger, M. Kumari, S. Eder, G. Schoiswohl, N.
Wongsiriroj, N.M. Pollak, F.P. Radner, K. Preiss-Landl, T. Kolbe, T. Rulicke, B.
Pieske, M. Trauner, A. Lass, R. Zimmermann, G. Hoeﬂer, S. Cinti, E.E. Kershaw,
P. Schrauwen, F. Madeo, B. Mayer, R. Zechner, ATGL-mediated fat catabolism
regulates cardiac mitochondrial function via PPAR-alpha and PGC-1, Nat. Med.
17 (2011) 1076–1085.
[259] O. Muzik, T.J. Mangner, J.G. Granneman, Assessment of oxidative metabolism in
brown fat using PET imaging, Front Endocrinol (Lausanne) 3 (2012) 15.
[260] D.C. Shing, M. Trubia, F. Marchesi, E. Radaelli, E. Belloni, C. Tapinassi, E. Scanziani, C.
Mecucci, B. Crescenzi, I. Lahortiga, M.D. Odero, G. Zardo, A. Gruszka, S. Minucci, P.P.
Di Fiore, P.G. Pelicci, Overexpression of sPRDM16 coupled with loss of p53 induces
myeloid leukemias in mice, J. Clin. Invest. 117 (2007) 3696–3707.
[261] P. Viatour, J. Sage, Newly identiﬁed aspects of tumor suppression by RB, Dis.
Model. Mech. 4 (2011) 581–585.
[262] L. Sun, H. Xie, M.A. Mori, R. Alexander, B. Yuan, S.M. Hattangadi, Q. Liu, C.R. Kahn,
H.F. Lodish, Mir193b-365 is essential for brown fat differentiation, Nat. Cell Biol.
13 (2011) 958–965.
[263] M. Trajkovski, K. Ahmed, C.C. Esau, M. Stoffel, MyomiR-133 regulates brown fat
differentiation through Prdm16, Nat. Cell Biol. 14 (2012) 1330–1335.
[264] M. Mori, H. Nakagami, G. Rodriguez-Araujo, K. Nimura, Y. Kaneda, Essential role
for miR-196a in brown adipogenesis of white fat progenitor cells, PLoS Biol. 10
(2012).
[265] T.T. Tran, C.R. Kahn, Transplantation of adipose tissue and stem cells: role in
metabolism and disease, Nat. Rev. Endocrinol. 6 (2010) 195–213.
[266] M. Nishio, T. Yoneshiro, M. Nakahara, S. Suzuki, K. Saeki, M. Hasegawa, Y. Kawai,
H. Akutsu, A. Umezawa, K. Yasuda, K. Tobe, A. Yuo, K. Kubota, M. Saito, K. Saeki,
Production of functional classical brown adipocytes from human pluripotent
stem cells using speciﬁc hemopoietin cocktail without gene transfer, Cell
Metab. 16 (2012) 394–406.
[267] T. Ahfeldt, R.T. Schinzel, Y.-K. Lee, D. Hendrickson, A. Kaplan, D.H. Lum, R.
Camahort, F. Xia, J. Shay, E.P. Rhee, C.B. Clish, R.C. Deo, T. Shen, F.H. Lau, A.
Cowley, G. Mowrer, H. Al-Siddiqi, M. Nahrendorf, K. Musunuru, R.E. Gerszten,
J.L. Rinn, C.A. Cowan, Programming human pluripotent stem cells into white
and brown adipocytes, Nat. Cell Biol. 14 (2012) 209–219.
